<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Standard immunizations for children and adolescents: Overview</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Standard immunizations for children and adolescents: Overview</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Standard immunizations for children and adolescents: Overview</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jan E Drutz, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Teresa K Duryea, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Morven S Edwards, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Diane Blake, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 18, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Routine immunization schedules vary from country to country. This topic will provide an overview of immunization for children and adolescents in the United States. Immunization schedules for other countries are available through the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fimmunizationdata.who.int%2Flisting.html%3Ftopic%3Dvaccine-schedule%26location%3D&amp;token=c1aMGh80n5JfqNiS4zUVhkGZJHzJhW7hYZJMwrVG0LFEFjNX7MxA62uBiY6p7F6hXgl8VfAnRnqUWG6LumPYIJJ9nBP597SAHqgFR7nC42s%3D&amp;TOPIC_ID=2876" target="_blank">World Health Organization</a>.</p><p>Detailed information about individual vaccines, vaccine refusal or hesitancy, and vaccination for adults is provided separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/101483.html" rel="external">"Hepatitis B virus immunization in infants, children, and adolescents"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6023.html" rel="external">"Rotavirus vaccines for infants"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2844.html" rel="external">"Diphtheria, tetanus, and pertussis immunization in children 6 weeks through 6 years of age"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6022.html" rel="external">"Prevention of <i>Haemophilus influenzae</i> type b infection"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6053.html" rel="external">"Pneumococcal vaccination in children"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2695.html" rel="external">"Poliovirus vaccination"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5960.html" rel="external">"Seasonal influenza in children: Prevention with vaccines"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/101273.html" rel="external">"Measles, mumps, and rubella immunization in infants, children, and adolescents"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/8275.html" rel="external">"Vaccination for the prevention of chickenpox (primary varicella infection)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3900.html" rel="external">"Hepatitis A virus infection: Treatment and prevention"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2838.html" rel="external">"Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3901.html" rel="external">"Meningococcal vaccination in children and adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/8325.html" rel="external">"Human papillomavirus vaccination"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2846.html" rel="external">"Standard childhood vaccines: Caregiver hesitancy or refusal"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3884.html" rel="external">"Standard immunizations for nonpregnant adults"</a>.)</p><p></p><p class="headingAnchor" id="H81498659"><span class="h1">BENEFITS OF VACCINES</span><span class="headingEndMark"> — </span>Immunization is one of the most effective preventive health measures  (<a class="graphic graphic_figure graphicRef58899" href="/d/graphic/58899.html" rel="external">figure 1</a>) [<a href="#rid1">1-3</a>]. According to <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.immunize.org%2Fwp-content%2Fuploads%2Fcatg.d%2Fp4037.pdf&amp;token=gAXTW7Qg3fMkyTN6R9FEEnFBwptswbkgNauqj53jNA7zOc6BxU7ySwPJAeHXEZnFzo0IcX5YTadDeAWS4Z5A8Z1hTih2EOb2FsSGffdO%2Fxs%3D&amp;TOPIC_ID=2876" target="_blank">data</a> from the United States Centers for Disease Control and Prevention (CDC), the number of cases of most vaccine-preventable illnesses declined by &gt;90 percent after routine childhood immunizations were introduced [<a href="#rid4">4</a>].</p><p>Vaccination programs directly benefit the immunized child. They also indirectly benefit unimmunized persons through community ("herd") immunity. Community immunity occurs when the portion of the population that is immune to the infection is large enough to decrease the risk of transmission [<a href="#rid5">5,6</a>]. Community immunity protects children who are too young for immunization and persons with contraindications to vaccines. It relies on the majority of the population receiving routinely recommended immunizations. (See <a class="local">'Vaccination coverage'</a> below.)</p><p class="headingAnchor" id="H645243885"><span class="h1">ROUTINE SCHEDULE</span><span class="headingEndMark"> — </span>In the United States, the routine immunization schedules are updated annually for infants and children &lt;7 years old  (<a class="graphic graphic_figure graphicRef82617" href="/d/graphic/82617.html" rel="external">figure 2A</a>) and children/adolescents ≥7 years old  (<a class="graphic graphic_figure graphicRef58209" href="/d/graphic/58209.html" rel="external">figure 2B</a>). The schedule is recommended by the Advisory Committee on Immunization Practices and approved by the Centers for Disease Control and Prevention, American Academy of Pediatrics, American Academy of Family Physicians, American College of Obstetricians and Gynecologists, American College of Nurse-Midwives, American Academy of Physician Assistants, and National Association of Pediatric Nurse Practitioners [<a href="#rid7">7</a>].</p><p>Failure by health care providers, parents, and other caregivers to adhere to the recommended immunization schedules, including the timing of immunizations, leaves children susceptible to life-threatening vaccine-preventable diseases. (See  <a class="medical medical_review" href="/d/html/2846.html" rel="external">"Standard childhood vaccines: Caregiver hesitancy or refusal", section on 'Consequences of vaccine refusal'</a>.)</p><p class="headingAnchor" id="H3167808447"><span class="h2">Infants and children</span><span class="headingEndMark"> — </span>Immunizations that are routinely recommended for infants and children in the United States are usually administered at health supervision visits  (<a class="graphic graphic_figure graphicRef82617" href="/d/graphic/82617.html" rel="external">figure 2A</a>). However, every visit provides an opportunity to update vaccines. Multiple injections are required at most visits. The use of combination vaccines (eg, diphtheria, tetanus, acellular pertussis (DTaP)/hepatitis B (HepB)/inactivated <a class="drug drug_pediatric" data-topicid="12967" href="/d/drug information/12967.html" rel="external">poliovirus vaccine</a> (IPV) [Pediarix]; DTaP/<em>Haemophilus influenzae</em> type b (Hib)/IPV [Pentacel]; measles, mumps, and rubella (MMR)/varicella [ProQuad]; and DTaP/IPV [Kinrix]) can help to reduce the number of injections at each visit and improve vaccination coverage [<a href="#rid8">8-11</a>].</p><p>Immunizations routinely recommended for infants and children in the United States include [<a href="#rid12">12</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hepatitis B vaccine</strong> – HepB vaccine is routinely recommended within 24 hours of birth, at age 1 through 2 months, and at age 6 through 12 months  (<a class="graphic graphic_table graphicRef76345 graphicRef55139" href="/d/graphic/76345.html" rel="external">table 1A-B</a>). HepB vaccine is inactivated. It is administered intramuscularly (IM).</p><p></p><p class="bulletIndent1">Immunization against hepatitis B virus for infants, children, and adolescents is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/101483.html" rel="external">"Hepatitis B virus immunization in infants, children, and adolescents"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rotavirus vaccine</strong> – The routine schedule for rotavirus vaccine depends upon the vaccine formulation  (<a class="graphic graphic_table graphicRef70478" href="/d/graphic/70478.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The pentavalent human-bovine rotavirus reassortant vaccine (RV5) is administered at 2, 4, and 6 months of age.</p><p class="bulletIndent2"><span class="glyph">•</span>The attenuated human rotavirus vaccine (RV1) is administered at 2 and 4 months of age.</p><p></p><p class="bulletIndent1">Both <a class="drug drug_pediatric" data-topicid="13075" href="/d/drug information/13075.html" rel="external">rotavirus vaccines</a> are live attenuated viral vaccines. They are administered orally.</p><p></p><p class="bulletIndent1">Rotavirus immunization is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/6023.html" rel="external">"Rotavirus vaccines for infants"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diphtheria, tetanus, and/or pertussis vaccines</strong> – <a class="drug drug_pediatric" data-topicid="12763" href="/d/drug information/12763.html" rel="external">DTaP vaccine</a> is routinely recommended for infants and children at ages 2 months, 4 months, 6 months, 15 through 18 months, and 4 through 6 years. Booster doses are required beginning at age 11 years. DTaP vaccine is an inactivated vaccine. It is administered IM.</p><p></p><p class="bulletIndent1">Diphtheria, tetanus, and pertussis immunization for children is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/2844.html" rel="external">"Diphtheria, tetanus, and pertussis immunization in children 6 weeks through 6 years of age"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>H. influenzae</em></strong><strong> type b conjugate vaccine</strong> – Hib conjugate vaccine is routinely recommended in a two- or three-dose primary series (at age 2 and 4 months or at age 2, 4, and 6 months, depending upon the vaccine formulation) with a booster dose at age 12 through 15 months  (<a class="graphic graphic_table graphicRef77170" href="/d/graphic/77170.html" rel="external">table 3</a>). Hib vaccines are inactivated vaccines. They are administered IM.</p><p></p><p class="bulletIndent1">Hib immunization is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/6022.html" rel="external">"Prevention of <i>Haemophilus influenzae</i> type b infection", section on 'Routine childhood immunization in the United States'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pneumococcal conjugate vaccine</strong> – The pneumococcal conjugate vaccine (either 15-valent [<a class="drug drug_pediatric" data-topicid="139114" href="/d/drug information/139114.html" rel="external">PCV15</a>]) or 20-valent [<a class="drug drug_pediatric" data-topicid="141485" href="/d/drug information/141485.html" rel="external">PCV20</a>]) is routinely recommended at age 2, 4, 6, and 12 through 15 months. PCV15 and PCV20 are inactivated vaccines. They are administered IM.</p><p></p><p class="bulletIndent1">Pneumococcal immunization for children is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/6053.html" rel="external">"Pneumococcal vaccination in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inactivated </strong><strong>poliovirus vaccine</strong> – IPV is routinely recommended at age 2 months, 4 months, 6 through 18 months, and 4 through 6 years  (<a class="graphic graphic_table graphicRef78224" href="/d/graphic/78224.html" rel="external">table 4</a>). IPV is administered IM or subcutaneously.</p><p></p><p class="bulletIndent1">Poliovirus immunization is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/2695.html" rel="external">"Poliovirus vaccination"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Influenza vaccine </strong>– Influenza immunization is recommended annually for all children ≥6 months of age, particularly those at high risk for complications  (<a class="graphic graphic_table graphicRef72029" href="/d/graphic/72029.html" rel="external">table 5</a>). Inactivated influenza vaccines (IIV) for children &lt;18 years are administered IM  (<a class="graphic graphic_table graphicRef79474" href="/d/graphic/79474.html" rel="external">table 6</a>). The <a class="drug drug_pediatric" data-topicid="12941" href="/d/drug information/12941.html" rel="external">live attenuated influenza vaccine</a> (LAIV) is administered intranasally.</p><p></p><p class="bulletIndent1">Influenza immunization in children is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/5960.html" rel="external">"Seasonal influenza in children: Prevention with vaccines"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>COVID-19 vaccine</strong> – Coronavirus disease 2019 (COVID-19) vaccination is recommended for infants and children ≥6 months of age. The dose and schedule vary with age and vaccine formulation as summarized in the table  (<a class="graphic graphic_table graphicRef130711" href="/d/graphic/130711.html" rel="external">table 7</a>) and discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/129849.html" rel="external">"COVID-19: Vaccines"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Measles, mumps, and rubella vaccine</strong> – MMR vaccine is routinely recommended at age 12 through 15 months and age 4 through 6 years. MMR is a live attenuated virus vaccine. It is administered subcutaneously.</p><p></p><p class="bulletIndent1">Immunization against measles, mumps, and rubella is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/101273.html" rel="external">"Measles, mumps, and rubella immunization in infants, children, and adolescents"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Varicella vaccine</strong> – Varicella-zoster virus (VZV; chickenpox) vaccine is routinely recommended at age 12 through 15 months and age 4 through 6 years. VZV vaccine is a live attenuated virus vaccine. It is administered subcutaneously.</p><p></p><p class="bulletIndent1">Immunization against varicella-zoster virus is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/8275.html" rel="external">"Vaccination for the prevention of chickenpox (primary varicella infection)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hepatitis A vaccine</strong> – Two doses of hepatitis A virus (HepA) vaccine are routinely recommended between 12 and 24 months; the doses should be separated by at least six months [<a href="#rid13">13</a>]. HepA vaccine is an inactivated vaccine. It is administered IM.</p><p></p><p class="bulletIndent1">Immunization against hepatitis A virus is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/3900.html" rel="external">"Hepatitis A virus infection: Treatment and prevention"</a>.)</p><p></p><p class="headingAnchor" id="H4095257626"><span class="h2">Adolescents</span><span class="headingEndMark"> — </span>Most of the immunizations that are routinely recommended for adolescents in the United States are administered at 11 through 12 years or 16 years of age  (<a class="graphic graphic_figure graphicRef58209" href="/d/graphic/58209.html" rel="external">figure 2B</a>) [<a href="#rid12">12,14</a>]. However, every visit provides an opportunity to update and/or complete an adolescent's immunizations [<a href="#rid15">15</a>]. (See <a class="local">'Catch-up schedule'</a> below.)</p><p>Immunizations that are routinely recommended for adolescents in the United States include [<a href="#rid12">12</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tetanus, diphtheria, and acellular pertussis vaccine</strong> – A dose of tetanus, diphtheria, and acellular pertussis (Tdap) vaccine is routinely recommended at age 11 through 12 years. Tdap is an inactivated vaccine. It is administered IM.</p><p></p><p class="bulletIndent1">Immunization against tetanus, diphtheria, and pertussis for older children and adolescents is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/2838.html" rel="external">"Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Meningococcal vaccines</strong> – <a class="drug drug_pediatric" data-topicid="12931" href="/d/drug information/12931.html" rel="external">Quadrivalent meningococcal conjugate vaccine</a> (MenACWY) is routinely recommended at age 11 through 12 years and at age 16 years. MenACWY is an inactivated vaccine. It is administered IM.</p><p></p><p class="bulletIndent1">Meningococcal serogroup B vaccines are not routinely recommended for adolescents who are not at increased risk for meningococcal disease. However, they may be given to adolescents and young adults age 16 through 23 years (age 16 through 18 years is preferred) in the context of shared decision-making (eg, considering the severity of meningococcal disease, the epidemiology of serogroup B meningococcal disease, the duration of protection) [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1">Immunization against meningococcal disease is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/3901.html" rel="external">"Meningococcal vaccination in children and adults", section on 'Routine immunization of adolescents and young adults'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Human papillomavirus vaccine </strong>– Two doses of the 9-valent human papillomavirus (HPV) vaccine are routinely recommended for immune-competent adolescents 11 through 12 years of age; the doses should be separated by at least six months [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1">If the adolescent is immunocompromised or the HPV vaccine series is initiated at ≥15 years of age, three doses of HPV vaccine are recommended; the second dose should be given one to two months after the first dose; the third dose should be given six months after the first dose. (See  <a class="medical medical_review" href="/d/html/8325.html" rel="external">"Human papillomavirus vaccination", section on 'Indications and age range'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Influenza vaccine</strong> – Influenza immunization is recommended annually for all children ≥6 months of age, particularly those at high risk for complications  (<a class="graphic graphic_table graphicRef72029" href="/d/graphic/72029.html" rel="external">table 5</a>). IIV for children are administered IM. LAIV is administered intranasally. (See  <a class="medical medical_review" href="/d/html/5960.html" rel="external">"Seasonal influenza in children: Prevention with vaccines"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>COVID-19 vaccine</strong> – COVID-19 vaccination is recommended for all adolescent and adult patients. The dose and schedule vary with age and vaccine formulation as summarized in the table  (<a class="graphic graphic_table graphicRef130711" href="/d/graphic/130711.html" rel="external">table 7</a>) and discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/129849.html" rel="external">"COVID-19: Vaccines"</a>.)</p><p></p><p class="headingAnchor" id="H3005310320"><span class="h1">CATCH-UP SCHEDULE</span><span class="headingEndMark"> — </span>Children who are behind on vaccines should be caught up using the minimum intervals between doses  (<a class="graphic graphic_table graphicRef58271 graphicRef72079" href="/d/graphic/58271.html" rel="external">table 8A-B</a>). It is <strong>not</strong> necessary to restart the series even when the interval between doses is prolonged [<a href="#rid18">18,19</a>].</p><p>The Centers for Disease Control and Prevention has developed "job aids" to provide guidance for catch-up of individual vaccines:</p><p class="bulletIndent1"><span class="glyph">●</span>Pneumococcal conjugate vaccine</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fschedules%2Fdownloads%2Fchild%2Fjob-aids%2Fpneumococcal.pdf&amp;token=tOdEoTf5ljtGtizH0uwcXEKM5gSRP2vrRdxpzqImsy7aSzJPolEa7Q%2FJQT45HcKqboS2FnKkHm4aPaLGyja%2FsPGJiuxYmPkD4WPrG7e%2BrMo%3D&amp;TOPIC_ID=2876" target="_blank">Recommendations table</a> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww2a.cdc.gov%2Fvaccines%2Fm%2Fpneumo%2Fpneumo.html&amp;token=N8qVJSrBCrbuXuD7GKvcN%2BGkwQLQ7IKRD0WskUEB1oAU%2F3x%2FQKivGUThAjjVztADglJJfWzbGBaZOZmHWPdaEw%3D%3D&amp;TOPIC_ID=2876" target="_blank">Pneumococcal recommendations vaccine advisor tool</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>H. influenzae</em> type b (Hib)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fschedules%2Fdownloads%2Fchild%2Fjob-aids%2Fhib-actHib.pdf&amp;token=OB1%2FtTh%2Fb3Dl8verH6gfaCtENVJJgiToUBCZTdAjOoPIbQfvgddoKt7x%2BWD2BpqybLlAJeISBqHRd%2BvZOdgkR3XzNjQjikJ39dDw2R5bseY%3D&amp;TOPIC_ID=2876" target="_blank">Previous immunization with ActHiB, Pentacel, Menhibrix (discontinued in 2016), or unknown Hib vaccine</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fschedules%2Fdownloads%2Fchild%2Fjob-aids%2Fhib-pedvax.pdf&amp;token=N%2BvlL8QThFnePHKsoQZRmAZ7%2B55YAU2KEyW88UJFW7wOC8ZT1aBrehqifvIkGKGB%2FDPb1V41D5JUaAQLgQmZuNOWJW0%2Bcb5dqdWVVyzrbLU%3D&amp;TOPIC_ID=2876" target="_blank">Previous immunization with PedVaxHIB or Comvax (discontinued in 2014)</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fschedules%2Fdownloads%2Fchild%2Fjob-aids%2Fdtap.pdf&amp;token=tOdEoTf5ljtGtizH0uwcXFuJNNpgpl1WuO1vtEtc55yzZoInNMcBIBX4q1qHKaWwgtKS8lcCoRpV%2FKpaijDWLAgYjp2Kbo4rvaSUVWNsaN0%3D&amp;TOPIC_ID=2876" target="_blank">Diphtheria, tetanus, and pertussis-containing vaccines</a> for children 4 months through 6 years of age </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tetanus, diphtheria, and pertussis containing vaccines </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fschedules%2Fdownloads%2Fchild%2Fjob-aids%2Ftdap-1.pdf&amp;token=vr5QCBLSIwEY9mZnp8bvMC5MobD1XllEJvDBpNkPVylqtzO9KzD0okhdTiwIGculp26%2FCraZGA9V5iRzl7y98teJfesSEQualSECDdF7kb4%3D&amp;TOPIC_ID=2876" target="_blank">For children 7 through 9 years of age</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fschedules%2Fdownloads%2Fchild%2Fjob-aids%2Ftdap-2.pdf&amp;token=qJr552gIhnzBx34csL0PDDYGC9HJbA5tRuusdO3kgbYp3Gph%2FxJ5hqmUIOPbH6x1ZZAz%2F2cTfnrr%2Fk8izyaYWxPU4eAmeOWqbuJafyjbiKc%3D&amp;TOPIC_ID=2876" target="_blank">For children 10 through 18 years of age</a> </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fschedules%2Fdownloads%2Fchild%2Fjob-aids%2Fipv.pdf&amp;token=gZfeCbi2ki2EOSjqeRrnIE926obxbXKch7IFeV2v2aG1x9SviqyRn0fBeY2j3amSnPFnfYACkpfRPI7Z6pv6hUVf7qbJVgu2OtuUeFzesg8%3D&amp;TOPIC_ID=2876" target="_blank">Inactivated polio vaccine</a></p><p></p><p class="headingAnchor" id="H2326773998"><span class="h1">SPECIAL CIRCUMSTANCES</span></p><p class="headingAnchor" id="H359865919"><span class="h2">Vaccine hesitancy or refusal</span><span class="headingEndMark"> — </span>The approach to parents who are hesitant to have their child vaccinated or refuse childhood vaccines is discussed separately. (See  <a class="medical medical_review" href="/d/html/2846.html" rel="external">"Standard childhood vaccines: Caregiver hesitancy or refusal", section on 'Approach to management'</a>.)</p><p class="headingAnchor" id="H1668518791"><span class="h2">Unknown or uncertain immunization record</span><span class="headingEndMark"> — </span>For children with an unknown or uncertain immunization record, acceptable approaches include [<a href="#rid20">20,21</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Serologic testing for antibodies to vaccine-preventable illnesses  (<a class="graphic graphic_table graphicRef87689" href="/d/graphic/87689.html" rel="external">table 9</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Age-appropriate revaccination (as if the child were unvaccinated)</p><p class="bulletIndent1"><span class="glyph">●</span>A combination of both approaches</p><p></p><p>The Centers for Disease Control and Prevention Advisory Committee on Immunization Practices generally recommends age-appropriate revaccination [<a href="#rid22">22</a>].</p><p>The approach to immunization of children in the United States who have unknown or uncertain immunization history generally is the same as that for children vaccinated outside the United States who have unknown or uncertain immunizations. It is discussed separately. (See  <a class="medical medical_review" href="/d/html/89453.html" rel="external">"International adoption: Immunization considerations", section on 'Unknown or uncertain immunization'</a>.)</p><p class="headingAnchor" id="H2656333058"><span class="h2">Dengue endemic areas</span><span class="headingEndMark"> — </span>Dengue endemic United States territories and sovereign states in free association with the United States include [<a href="#rid23">23</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>American Samoa</p><p class="bulletIndent1"><span class="glyph">●</span>Federated States of Micronesia</p><p class="bulletIndent1"><span class="glyph">●</span>Republic of Marshall Islands</p><p class="bulletIndent1"><span class="glyph">●</span>Republic of Palau</p><p class="bulletIndent1"><span class="glyph">●</span>Puerto Rico</p><p class="bulletIndent1"><span class="glyph">●</span>United States Virgin Islands</p><p></p><p>A three-dose series of <a class="drug drug_pediatric" data-topicid="121309" href="/d/drug information/121309.html" rel="external">dengue tetravalent live vaccine</a> is recommended for children age 9 through 16 years who live in these dengue endemic areas <strong>and</strong> have laboratory confirmation of previous dengue infection [<a href="#rid23">23</a>]. Confirmation of previous dengue infection is necessary because this vaccine is associated with severe dengue disease in people who have their first dengue infection after dengue vaccination. Laboratory confirmation is based upon the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fndc.services.cdc.gov%2Fcase-definitions%2Fdengue-virus-infections-2015%2F&amp;token=2tcCGrEdRr%2Fw4D7BOrpZsI3K2MxNc4sXV6CIYHfZJlOLrdfSbZPBVEVuaIXvy8ZWfDv%2BVfkSsI494GRRoXV51LRqy0QcsFfjRpCcSS0rXek%3D&amp;TOPIC_ID=2876" target="_blank">2015 Centers for Disease Control and Prevention case definition</a> or a highly accurate serodiagnostic screening test [<a href="#rid23">23,24</a>]. Suggested intervals between prevaccination serologic testing for previous dengue infection and <a class="drug drug_pediatric" data-topicid="83878" href="/d/drug information/83878.html" rel="external">immune globulin</a> or blood products are discussed below. (See <a class="local">'Other special circumstances'</a> below.)</p><p>The three 0.5 mL doses are administered subcutaneously and should be separated by six months. (See  <a class="medical medical_review" href="/d/html/3030.html" rel="external">"Dengue virus infection: Prevention and treatment", section on 'CYD-TDV (Dengvaxia)'</a>.)</p><p class="headingAnchor" id="H442888927"><span class="h2">Other special circumstances</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preterm infants </strong>– The routine immunization schedule, dose, intervals, and contraindications/precautions are the same for preterm infants (born at &lt;37 weeks' gestation) as for infants and children who were born at ≥37 weeks' gestation, with the exception of hepatitis B (HepB) vaccine [<a href="#rid25">25</a>]. For infants who weigh &lt;2 kg (4.4 pounds) at birth <strong>and</strong> are born to women who are hepatitis B surface antigen negative, the first dose of HepB vaccine is postponed until hospital discharge or 30 days of age, whichever is earlier  (<a class="graphic graphic_table graphicRef55139" href="/d/graphic/55139.html" rel="external">table 1B</a>). (See  <a class="medical medical_review" href="/d/html/101483.html" rel="external">"Hepatitis B virus immunization in infants, children, and adolescents", section on 'Routine infant immunization'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunocompromised children </strong>–<strong> </strong>Immunization of children with primary immunodeficiency, asplenia/hyposplenia, and human immunodeficiency virus (HIV) discussed separately. (See  <a class="medical medical_review" href="/d/html/106521.html" rel="external">"Immunizations in patients with inborn errors of immunity"</a> and  <a class="medical medical_review" href="/d/html/3706.html" rel="external">"Immunizations in persons with HIV"</a> and  <a class="medical medical_review" href="/d/html/1412.html" rel="external">"Prevention of infection in patients with impaired splenic function", section on 'Vaccinations'</a>.)</p><p></p><p class="bulletIndent1">Specific caveats regarding immunization in children with secondary immunodeficiency (eg, high-dose glucocorticoids) or who are to initiate immunosuppressive therapies (including antitumor necrosis factor agents, such as <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a> or <a class="drug drug_pediatric" data-topicid="13077" href="/d/drug information/13077.html" rel="external">adalimumab</a>) are discussed in topics related to individual vaccines. For example, (see  <a class="medical medical_review" href="/d/html/101273.html" rel="external">"Measles, mumps, and rubella immunization in infants, children, and adolescents", section on 'Contraindications'</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infants with in utero exposure to certain antitumor necrosis factor agents</strong> – Expert groups recommend avoidance of live-attenuated vaccines for infants with in utero exposure to certain antitumor necrosis factor agents (eg, <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a>, <a class="drug drug_pediatric" data-topicid="13077" href="/d/drug information/13077.html" rel="external">adalimumab</a>, <a class="drug drug_pediatric" data-topicid="129934" href="/d/drug information/129934.html" rel="external">golimumab</a>) because the infants may have detectable serum levels of the drug for up to nine months [<a href="#rid26">26-28</a>]. The duration of avoidance varies with the agent, but it is generally at least six months. Refer to the <a class="external" href="/drug-interactions">drug interactions program</a> included within UpToDate for details.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Close contacts of immunocompromised persons</strong> – Close (eg, household) contacts of immunocompromised persons should receive all routinely recommended vaccines  (<a class="graphic graphic_figure graphicRef82617 graphicRef58209" href="/d/graphic/82617.html" rel="external">figure 2A-B</a>) [<a href="#rid29">29</a>]. Close contacts of immunocompromised persons should not receive <a class="drug drug_pediatric" data-topicid="139319" href="/d/drug information/139319.html" rel="external">smallpox vaccine</a>, which is not routinely recommended for children or adolescents. (See  <a class="medical medical_review" href="/d/html/8296.html" rel="external">"Vaccines to prevent smallpox, mpox (monkeypox), and other orthopoxviruses"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children and adolescents with increased risk of bleeding</strong> – For children and adolescents at increased risk of bleeding following intramuscular (IM) injections, we suggest consultation with the child's hematologist. The Advisory Committee on Immunization Practices best practice guidelines indicate that IM injections can be administered to a child or adolescent with a bleeding disorder if a clinician familiar with the patient's bleeding risk determines that the vaccine can be administered with reasonable safety [<a href="#rid22">22</a>]. Additional suggestions include [<a href="#rid22">22,30</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If possible, schedule IM injections shortly after administration of clotting factors or before administration of anticoagulant medications</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Use a 23-gauge or smaller caliber needle</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Apply firm pressure on the site, without rubbing, for at least two minutes after injection</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnant adolescents</strong> – Live vaccines (eg, measles, mumps, and rubella [MMR] vaccine, <a class="drug drug_pediatric" data-topicid="13006" href="/d/drug information/13006.html" rel="external">varicella vaccine</a>, MMR-varicella vaccine) and human papillomavirus vaccine should be avoided during pregnancy. The approach to immunizations during pregnancy is discussed separately. (See  <a class="medical medical_review" href="/d/html/442.html" rel="external">"Immunizations during pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children or close contacts of pregnant women</strong> – Children and close contacts of pregnant women should receive routinely recommended vaccines, including live virus vaccines (eg, MMR vaccine, <a class="drug drug_pediatric" data-topicid="13006" href="/d/drug information/13006.html" rel="external">varicella vaccine</a>, rotavirus vaccine) [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recent or anticipated administration of </strong><strong>immune globulin</strong><strong> or blood products</strong> – MMR and varicella vaccines should not be administered on the same day as <a class="drug drug_pediatric" data-topicid="83878" href="/d/drug information/83878.html" rel="external">immune globulin</a> or for several months after immune globulin or blood products  (<a class="graphic graphic_table graphicRef72640" href="/d/graphic/72640.html" rel="external">table 10</a>). Immune globulin and blood products contain antibodies, which can interfere with the vaccine response.</p><p></p><p class="bulletIndent1">If <a class="drug drug_pediatric" data-topicid="83878" href="/d/drug information/83878.html" rel="external">immune globulin</a> or blood products must be given within 14 days after administration of MMR or <a class="drug drug_pediatric" data-topicid="13006" href="/d/drug information/13006.html" rel="external">varicella vaccine</a>, another dose of the vaccine should be administered after the suggested interval  (<a class="graphic graphic_table graphicRef72640" href="/d/graphic/72640.html" rel="external">table 10</a>).</p><p></p><p class="bulletIndent1">Although the immunogenicity and safety of dengue vaccine after administration of antibody-containing products have not been studied, the ACIP recommends delaying prevaccination serologic testing for a history of dengue infection until ≥12 months after receiving <a class="drug drug_pediatric" data-topicid="83878" href="/d/drug information/83878.html" rel="external">immune globulin</a> or blood products. Antibody-containing blood products may generate a false positive test for dengue [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunizations for travel</strong> – Immunizations for travel are discussed separately. (See  <a class="medical medical_review" href="/d/html/3890.html" rel="external">"Immunizations for travel"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children vaccinated outside the United States</strong> – The approach to immunization of children who were vaccinated outside the United States is the same as that for internationally adopted children. It is discussed separately. (See  <a class="medical medical_review" href="/d/html/89453.html" rel="external">"International adoption: Immunization considerations"</a>.)</p><p></p><p class="headingAnchor" id="H3599497874"><span class="h1">VACCINE ADMINISTRATION</span><span class="headingEndMark"> — </span>The Advisory Committee on Immunization Practices (ACIP) provides best practice recommendations for vaccine administration, including <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fhcp%2Facip-recs%2Fgeneral-recs%2Ftiming.html%23t-02&amp;token=mYAdTABtjfTUPLPFv6f%2FlNbSwAfD2TgcEIHCelQLOkA4aDVnguVXuxeKzQa65jPNHCI3rsWnpLRTRhZ4KP4K7OqgkSsYT7Gw2xg8H5wOb9Q%3D&amp;TOPIC_ID=2876" target="_blank">minimum ages and intervals between vaccine doses</a>, as well as the recommended dose, route, and site of administration for individual vaccines  (<a class="graphic graphic_table graphicRef114641" href="/d/graphic/114641.html" rel="external">table 11</a>) [<a href="#rid31">31</a>].</p><p>Variations from these recommendations may result in invalid doses. (See <a class="local">'Invalid doses'</a> below.)</p><p class="headingAnchor" id="H1184246441"><span class="h2">Preadministration counseling</span><span class="headingEndMark"> — </span>In the United States, the National Childhood Vaccine Injury Act requires clinicians to provide the relevant vaccine information statement(s) to the child's caregiver/legal guardian before vaccine administration. <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fhcp%2Fvis%2Fcurrent-vis.html&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLAH%2FK5ePuSCWLS93Qnaa3r%2F5qdQw%2FNYQGK1y%2BHqFU7TkRZLnBxvqrSwSUrCQcXZVSA%3D%3D&amp;TOPIC_ID=2876" target="_blank">Vaccine information statements</a> are available from the Centers for Disease Control and Prevention (CDC).</p><p>The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fhcp%2Facip-recs%2Fgeneral-recs%2Fcontraindications.html%23t-01&amp;token=6ueO%2FaxldHJpCyCaCNPb7mHVrSmDPVTmUZqlyjUwPWA2E%2BzSFV1qRAZwVZzcsMt7hVW5Sj%2B7i39F1S9Glgtnx1GqqYVj%2BNHr5juvqXVbacY%3D&amp;TOPIC_ID=2876" target="_blank">CDC website</a> provides a list of contraindications and precautions to vaccines commonly used for children and adolescents. The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.immunize.org%2Fhandouts%2Fscreening-vaccines.asp&amp;token=JoPMc1CmN2oIWcYPpaTQmxYM%2Fyx87JXeonrRcs%2BlBedyuCEhbdrHxLoebOHq0rE5ep11uey80%2BNPiYny7xwY8g%3D%3D&amp;TOPIC_ID=2876" target="_blank">Immunize.org</a> website provides screening checklists for contraindications or precautions. Contraindications and precautions for specific vaccines and combination vaccines are discussed in individual topics related to immunizations for children.</p><p>Educating parents/caregivers and patients about vaccine-related pain management may be helpful in reducing pain during and after injections [<a href="#rid32">32</a>]. Education tools that are freely available, including a pamphlet (available from the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cmaj.ca%2Fcontent%2F190%2F42%2FE1245%2Ftab-related-content&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlMKXVg4NHlb4r2kSJvPSr2j0sQUDa9avfVVwO%2F%2FzUZXIGZb%2BmiUEgQu85RlqgE%2Fssg%3D%3D&amp;TOPIC_ID=2876" target="_blank">Canadian Medical Association Journal</a>) and a <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.youtube.com%2Fwatch%3Fv%3D5Oqa1Fag5eQ%23action%3Dshare&amp;token=3BBziCZQDrEhIlt93szQloH6eZnp6PMXkxC7JnVMP%2FWmBRpzPg%2FFL3bV3DabCa2Tk5uOELXwK6RVebdBTPw6za8AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=2876" target="_blank">video</a>, have been developed for parents of newborn infants [<a href="#rid33">33,34</a>]. In a longitudinal randomized trial, provision of these tools to parents in the nursery was associated with increased use of pain reduction strategies for infant immunizations [<a href="#rid35">35</a>]. (See <a class="local">'Reducing injection pain'</a> below.)</p><p class="headingAnchor" id="H5"><span class="h2">Injectable vaccines</span><span class="headingEndMark"> — </span>Most of the routinely recommended childhood vaccines are injected intramuscularly (IM) or subcutaneously  (<a class="graphic graphic_table graphicRef114641" href="/d/graphic/114641.html" rel="external">table 11</a>). The preferred position of the child and site of injection vary with age and route of injection  (<a class="graphic graphic_table graphicRef114644" href="/d/graphic/114644.html" rel="external">table 12</a>). The injection site should be as free as possible from risk of local neural, vascular, or tissue injury [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H3928209354"><span class="h3">Patient position</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infants &lt;12 months</strong> – Infants &lt;12 months usually are held by their caregiver during injections; skin-to-skin contact is preferred for infants younger than one month [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>12 months through 2 years</strong> – Children 12 months through 2 years usually are held by their caregiver during injections  (<a class="graphic graphic_figure graphicRef114649" href="/d/graphic/114649.html" rel="external">figure 3</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>3 years and older</strong> – Children 3 years through 11 years usually are seated during injections; they may be held by their caregiver. Adolescents ≥12 years and young adults may be seated or lying down during injections.</p><p></p><p class="headingAnchor" id="H1833949965"><span class="h3">Immunization technique</span><span class="headingEndMark"> — </span>Injectable vaccines should be administered using sterile technique [<a href="#rid31">31</a>]. It is not necessary to change needles between drawing the vaccine into the syringe and injecting it. A new needle and a new syringe should be used for each injection.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intramuscular injection</strong> – The preferred site for IM injections varies with age:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Infants &lt;12 months – Anterolateral thigh (vastus lateralis)  (<a class="graphic graphic_figure graphicRef114647" href="/d/graphic/114647.html" rel="external">figure 4</a>) is preferred; if the anterolateral thigh cannot be used (eg, because it is covered by a cast), the ventrogluteal site  (<a class="graphic graphic_figure graphicRef114650" href="/d/graphic/114650.html" rel="external">figure 5</a>) can be used; the upper outer gluteal quadrant (the dorsogluteal site) of the buttock should be avoided because of the possibility of a suboptimal immune response [<a href="#rid37">37,38</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>12 months through 2 years – Anterolateral thigh is preferred, but the deltoid area of upper arm may be used.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>≥3 years – Deltoid area of upper arm  (<a class="graphic graphic_figure graphicRef114648" href="/d/graphic/114648.html" rel="external">figure 6</a>).</p><p></p><p class="bulletIndent1">For IM injections, a 22- to 25-gauge needle is recommended [<a href="#rid31">31,39</a>]. The suggested needle length varies with age, sex, and weight  (<a class="graphic graphic_table graphicRef60863" href="/d/graphic/60863.html" rel="external">table 13</a>). The needles should be long enough to reach the muscle but not so long as to penetrate underlying nerves, blood vessels, or bone [<a href="#rid31">31,40-45</a>]. Penetration into the bone can cause pain, damage to the periosteum, and detachment of the needle from the syringe [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1">The angle between the needle and the skin should be 90°. It is not necessary to pull back on the syringe plunger after needle insertion before IM injection [<a href="#rid31">31,47</a>]. The recommended sites for IM injections do not contain large blood vessels, and aspiration before injection may increase injection pain [<a href="#rid32">32,36,48,49</a>].</p><p></p><p class="bulletIndent1">For deltoid injections, in addition to using the appropriate size needle, the following steps should be taken to avoid inadvertent injection into the subdeltoid bursa or joint space, which may cause "shoulder injury related to vaccine administration" [<a href="#rid50">50-53</a>] (see <a class="local">'Local and systemic reactions'</a> below):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Both the patient and the vaccinator should be seated.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The arm should be completely exposed and lifted slightly out to the side (eg, with the hand placed on the ipsilateral hip), which causes the subdeltoid bursa to slide under the acromion for protection.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The needle should be inserted into the center of the deltoid muscle, midway between the acromion and the deltoid tuberosity (the insertion of the deltoid at the middle of the humerus), a point that falls in the middle one-third of an inverted triangle between the acromion and the deltoid tuberosity  (<a class="graphic graphic_figure graphicRef114648" href="/d/graphic/114648.html" rel="external">figure 6</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subcutaneous injection</strong> – The preferred site for subcutaneous injections varies with age:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Infants &lt;12 months – The fatty tissue over the anterolateral thigh is preferred  (<a class="graphic graphic_figure graphicRef114647" href="/d/graphic/114647.html" rel="external">figure 4</a>); the upper-outer triceps may be used if necessary.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>≥12 months – The fatty tissue over the upper-outer area of triceps is preferred.</p><p></p><p class="bulletIndent1">For subcutaneous injections, a 23- or 25-gauge needle 5/8 inch (16 mm) long is recommended [<a href="#rid45">45</a>]. The angle between the needle and skin should be 45°.</p><p></p><p class="headingAnchor" id="H416059916"><span class="h2">Oral vaccines</span><span class="headingEndMark"> — </span>Rotavirus is the only routine childhood vaccine that is administered orally. Administration of rotavirus vaccine is discussed separately. (See  <a class="medical medical_review" href="/d/html/6023.html" rel="external">"Rotavirus vaccines for infants", section on 'Administration'</a>.)</p><p class="headingAnchor" id="H680783462"><span class="h2">Intranasal vaccines</span><span class="headingEndMark"> — </span>The <a class="drug drug_pediatric" data-topicid="12941" href="/d/drug information/12941.html" rel="external">live attenuated influenza vaccine</a> (LAIV) is the only routine childhood vaccine that is administered intranasally; an <a class="drug drug_pediatric" data-topicid="12940" href="/d/drug information/12940.html" rel="external">inactivated influenza vaccine</a> that is administered IM is an alternative to intranasal injection. Indications for and administration of LAIV are discussed separately. (See  <a class="medical medical_review" href="/d/html/5960.html" rel="external">"Seasonal influenza in children: Prevention with vaccines", section on 'Route and dose'</a>.)</p><p class="headingAnchor" id="H2561276728"><span class="h2">Administration of multiple vaccines at one visit</span></p><p class="headingAnchor" id="H2672370466"><span class="h3">Timing and spacing</span><span class="headingEndMark"> — </span>There is no upper limit to the number of vaccines that may be administered at a single visit [<a href="#rid18">18,19,54</a>]. The vaccines should not be mixed in the same syringe unless the combination has been specifically approved by the US Food and Drug Administration.</p><p>Most <strong>routine</strong> vaccines for children and adolescents  (<a class="graphic graphic_figure graphicRef82617 graphicRef58209" href="/d/graphic/82617.html" rel="external">figure 2A-B</a>) can be administered on the same day (at different sites) without compromising effectiveness [<a href="#rid19">19,55-59</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inactivated vaccines</strong> – Two or more inactivated vaccines may be administered at the same visit as or at any interval before or after other inactivated vaccines with <strong>one exception</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>PCV and PPSV23</strong> – In persons who require both pneumococcal conjugate vaccine (PCV; eg, <a class="drug drug_pediatric" data-topicid="139114" href="/d/drug information/139114.html" rel="external">PCV15</a>) and the 23-valent <a class="drug drug_pediatric" data-topicid="12948" href="/d/drug information/12948.html" rel="external">pneumococcal polysaccharide vaccine</a> (PPSV23), PCV should be administered at least eight weeks before PPSV23.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inactivated and live vaccines</strong> – Inactivated and live vaccines  (<a class="graphic graphic_table graphicRef112956" href="/d/graphic/112956.html" rel="external">table 14</a>) may be administered at the same visit or at any interval between doses.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Live injectable or live intranasal vaccines</strong> – Two or more live injectable<strong> </strong> (<a class="graphic graphic_table graphicRef112956" href="/d/graphic/112956.html" rel="external">table 14</a>)<strong> </strong>vaccines (eg, measles, mumps, and rubella [MMR] vaccine, <a class="drug drug_pediatric" data-topicid="13006" href="/d/drug information/13006.html" rel="external">varicella vaccine</a>, dengue vaccine) or live<strong> </strong>intranasal vaccines (eg, <a class="drug drug_pediatric" data-topicid="12941" href="/d/drug information/12941.html" rel="external">live attenuated influenza vaccine</a>) may be administered on the same day or ≥28 days apart. <a class="drug drug_pediatric" data-topicid="13021" href="/d/drug information/13021.html" rel="external">Yellow fever vaccine</a> is an exception; it should be administered on the same day as or ≥30 days apart from other live injectable or live intranasal vaccines [<a href="#rid60">60</a>].</p><p></p><p class="bulletIndent1">Live oral rotavirus vaccine and live oral <a class="drug drug_pediatric" data-topicid="13020" href="/d/drug information/13020.html" rel="external">typhoid vaccine</a> may be administered on the same day as or at any interval before inactivated or live injectable vaccines. (See  <a class="medical medical_review" href="/d/html/3890.html" rel="external">"Immunizations for travel", section on 'Typhoid vaccine'</a>.)</p><p></p><p class="headingAnchor" id="H2827536485"><span class="h3">Site of injections</span><span class="headingEndMark"> — </span>When multiple injectable vaccines are required at a single visit, separate limbs should be used if possible, particularly for injections more likely to cause a local reaction (eg, diphtheria, tetanus, acellular pertussis vaccine and PCV) [<a href="#rid31">31,45,54</a>]. If necessary, two or more vaccines can be given in the same limb (usually the anterolateral thigh). If possible, the injections should be separated by at least 2.5 cm (1 inch) to avoid overlap of local reactions.</p><p>If a vaccine and <a class="drug drug_pediatric" data-topicid="83878" href="/d/drug information/83878.html" rel="external">immune globulin</a> preparation are administered at the same visit (eg, hepatitis B vaccine and <a class="drug drug_pediatric" data-topicid="13229" href="/d/drug information/13229.html" rel="external">hepatitis B immune globulin</a>; tetanus-containing vaccine and <a class="drug drug_pediatric" data-topicid="12834" href="/d/drug information/12834.html" rel="external">tetanus immune globulin</a>, <a class="drug drug_pediatric" data-topicid="12935" href="/d/drug information/12935.html" rel="external">hepatitis A vaccine</a> and immune globulin), different limbs should be used for each injection [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H991676486"><span class="h3">Order of administration</span><span class="headingEndMark"> — </span>When multiple vaccines are required at one visit, administering the least painful vaccines first may lessen immunization-related pain and distress [<a href="#rid32">32,36,61,62</a>].</p><p>For infants who require rotavirus vaccine, we suggest administering rotavirus vaccine before injectable vaccines. The oral rotavirus vaccine is flavored with sucrose, which may reduce the pain associated with subsequent injections [<a href="#rid32">32,63</a>]. (See <a class="local">'Reducing injection pain'</a> below.)</p><p>We also suggest administering other injectable vaccines before MMR and PCV. Administration of MMR and PCV is perceived to be more painful than administration of other injectable vaccines [<a href="#rid32">32,36,61,62</a>]. Information about the relative painfulness of other vaccines is lacking.</p><p>For infants &lt;12 months of age, if possible, we suggest administration of two injections simultaneously (by two health care providers at two different sites) rather than one after the other. Simultaneous injection may reduce injection pain for infants but does not appear to reduce distress for older children [<a href="#rid36">36,64</a>].</p><p class="headingAnchor" id="H397633702"><span class="h2">Reducing injection pain</span><span class="headingEndMark"> — </span>The pain associated with vaccine injections, particularly when multiple injections are required, is a source of anxiety for patients and caregivers [<a href="#rid65">65</a>]. Failure to adequately address pain at the time of vaccination may lead to subsequent delay or avoidance of vaccination [<a href="#rid32">32,47,66-69</a>].</p><p>Many of interventions for pain reduction discussed in the following sections (eg, topical anesthetics, breastfeeding, oral <a class="drug drug_pediatric" data-topicid="16103" href="/d/drug information/16103.html" rel="external">sucrose</a>, swaddling, distraction  (<a class="graphic graphic_table graphicRef114644" href="/d/graphic/114644.html" rel="external">table 12</a>)) are supported by randomized trials and meta-analyses [<a href="#rid36">36,70-73</a>]. Although the evidence of benefit is of low to moderate quality, the interventions are unlikely to be harmful. Combinations of interventions (eg, topical anesthetic and distraction) may be more effective than using a single strategy [<a href="#rid74">74</a>]. </p><p>Interventions with little support of benefit include warming the vaccine before administration and manual tactile stimulation (eg, pinching/pressing the skin near the injection site) during injection [<a href="#rid36">36</a>].</p><p>Our suggestions for reducing injection pain are generally in keeping with those of professional societies  (<a class="graphic graphic_table graphicRef114644" href="/d/graphic/114644.html" rel="external">table 12</a>) [<a href="#rid31">31,32,47</a>]:</p><p class="headingAnchor" id="H1273833208"><span class="h3">&lt;12 months of age</span><span class="headingEndMark"> — </span>For infants &lt;12 months of age, interventions that may be helpful in reducing injection pain include [<a href="#rid32">32,70,75</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Before injection</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Application of topical anesthetic agent (eg, cream, gel, patch) 30 to 60 minutes before injection if resources, availability, and time permit [<a href="#rid76">76,77</a>].</p><p></p><p class="bulletIndent2">The risk of methemoglobinemia with topical anesthetic agents is discussed separately. (See  <a class="medical medical_review" href="/d/html/7094.html" rel="external">"Methemoglobinemia", section on 'Topical anesthetics'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Feeding (at breast or with bottle) or nonnutritive sucking [<a href="#rid78">78,79</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For infants who require rotavirus vaccine – Administration of rotavirus vaccine.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For infants who do not require rotavirus vaccine – Administration of <a class="drug drug_pediatric" data-topicid="16103" href="/d/drug information/16103.html" rel="external">sucrose</a> 2 mL of 24 percent or 50 percent strength solution one to two minutes before injection [<a href="#rid75">75,80-83</a>]. Glucose 2 mL of a 30 percent strength solution can be used if sucrose is not available.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>During injection</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Feeding (at breast or with bottle) or nonnutritive sucking [<a href="#rid78">78,79,84</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If multiple injections are required and another clinician is available, administering two injections simultaneously (at different sites) rather than one after the other [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Administration of PCV <strong>after</strong> other injections.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Administration of MMR (if needed for travel or outbreak) <strong>after</strong> other injections.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>After injection</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Feeding (at breast or with bottle) or nonnutritive sucking [<a href="#rid78">78,79,85</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Swaddling, holding, side/stomach position, shushing, and/or rocking [<a href="#rid86">86</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Therapeutic administration of <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a> or <a class="drug drug_pediatric" data-topicid="13371" href="/d/drug information/13371.html" rel="external">ibuprofen</a>.</p><p></p><p class="headingAnchor" id="H1292549169"><span class="h3">12 months through 2 years</span><span class="headingEndMark"> — </span>For children 12 through 23 months years of age, interventions that may be helpful in reducing injection pain include [<a href="#rid32">32,70</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Before injection</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Application of topical anesthetic agent (eg, cream, gel, patch) 30 to 60 minutes before injection if resources, availability, and time permit.</p><p></p><p class="bulletIndent2">The risk of methemoglobinemia with topical anesthetic agents is discussed separately. (See  <a class="medical medical_review" href="/d/html/7094.html" rel="external">"Methemoglobinemia", section on 'Topical anesthetics'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Feeding (at breast or with bottle) or nonnutritive sucking (for children who continue to breastfeed or use a pacifier).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For children &lt;2 years – Administration of <a class="drug drug_pediatric" data-topicid="16103" href="/d/drug information/16103.html" rel="external">sucrose</a> [<a href="#rid87">87</a>]; the typical dose is 2 mL of 24 percent or 50 percent strength solution administered one to two minutes before injection; glucose 2 mL of a 30 percent strength solution can be used if sucrose is not available [<a href="#rid83">83</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>During injection</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Feeding (at breast or with bottle) or nonnutritive sucking (for children who continue to breastfeed or use a pacifier).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Distraction (eg, with a video, toy) [<a href="#rid71">71,88</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Administration of PCV and MMR <strong>after</strong> other injections.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>After injection</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Feeding (at breast or with bottle) or nonnutritive sucking (for children who continue to breastfeed or use a pacifier).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Stroking, rocking, or "blowing the pain away."</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Therapeutic administration of <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a> or <a class="drug drug_pediatric" data-topicid="13371" href="/d/drug information/13371.html" rel="external">ibuprofen</a>.</p><p></p><p class="headingAnchor" id="H269052016"><span class="h3">3 years and older</span><span class="headingEndMark"> — </span>For children ≥3 years, interventions that may be helpful in reducing injection pain include [<a href="#rid32">32,70,73,89</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Before injection</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Application of topical anesthetic agent (eg, cream, gel, patch) 30 to 60 minutes before injection if resources, availability, and time permit.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>During injection</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For children &lt;12 years – Video, music, verbal distraction, virtual reality distraction, or breathing distraction (eg, blowing bubbles or a pinwheel, deep breathing) [<a href="#rid71">71,88,90-92</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If PCV or MMR is necessary, administer <strong>after</strong> other injections.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>After injection</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Therapeutic administration of <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a> or <a class="drug drug_pediatric" data-topicid="13371" href="/d/drug information/13371.html" rel="external">ibuprofen</a>.</p><p></p><p class="headingAnchor" id="H3846494390"><span class="h2">Prophylactic medications</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Whether to administer</strong> – For infants and children who are receiving routine immunizations in the United States, we suggest <strong>not</strong> administering <strong>prophylactic</strong> antipyretic/analgesic agents. We suggest <strong>therapeutic</strong> antipyretic/analgesic agents (eg, <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a>, <a class="drug drug_pediatric" data-topicid="13371" href="/d/drug information/13371.html" rel="external">ibuprofen</a>) for infants and children who develop fever or painful local or systemic reaction following immunizations. (See <a class="local">'Reducing injection pain'</a> above.)</p><p></p><p class="bulletIndent1">A systematic review of randomized trials found that prophylactic <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a> reduced the risk of fever ≥38°C (100.4°F) 24 to 48 hours after primary immunization and booster immunization in children ≤6 years [<a href="#rid93">93</a>]. However, approximately one-half of children in the placebo groups remained afebrile. In addition, prophylactic administration of acetaminophen has been associated with decreased antibody concentrations for some vaccine antigens [<a href="#rid94">94-96</a>]. The clinical significance of this finding is uncertain, given that the antibody concentrations remained in the protective range.</p><p></p><p class="bulletIndent1">Our suggestion not to routinely administer prophylactic antipyretic/analgesic agents at the time of or within four hours after immunization is consistent with recommendations of the ACIP [<a href="#rid31">31</a>], the World Health Organization [<a href="#rid47">47</a>], and an independent Canadian clinical practice guideline [<a href="#rid32">32</a>]. However, in the United Kingdom, where the <a class="drug drug_pediatric" data-topicid="99754" href="/d/drug information/99754.html" rel="external">meningococcal serogroup B vaccine</a> (MenB-4C, Bexsero) is recommended during infancy, national guidelines advise administration of oral <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a> as soon as possible after MenB-4C immunization, four to six hours later, and four to six hours after that [<a href="#rid97">97,98</a>]. (See  <a class="medical medical_review" href="/d/html/3901.html" rel="external">"Meningococcal vaccination in children and adults", section on 'Serogroup B vaccines'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choice of agent</strong> – For infants and children whose caregivers choose to administer prophylactic antipyretics/analgesics, we suggest <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a> rather than <a class="drug drug_pediatric" data-topicid="13371" href="/d/drug information/13371.html" rel="external">ibuprofen</a>. We suggest that the first dose be administered within four hours after immunization.</p><p></p><p class="bulletIndent1">In a systematic review of the effect of prophylactic antipyretic administration, <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a> reduced the risk of fever and local and systemic reactions in children ≤6 years [<a href="#rid93">93</a>]. <a class="drug drug_pediatric" data-topicid="13371" href="/d/drug information/13371.html" rel="external">Ibuprofen</a> did not reduce the risk of fever and had inconsistent effects on the risk of local and systemic reactions. One of the included trials suggested that the acetaminophen dose given around the time of vaccination is more important than doses administered &gt;4 hours after immunization [<a href="#rid99">99</a>].</p><p></p><p class="headingAnchor" id="H1050348574"><span class="h1">NONSTANDARD VACCINE ADMINISTRATION</span></p><p class="headingAnchor" id="H1227501216"><span class="h2">Invalid doses</span><span class="headingEndMark"> — </span>Invalid doses need to be repeated because they may provide inadequate protection. Indications for repeating a vaccine dose include [<a href="#rid31">31,54</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The full age-appropriate dose of an injectable vaccine was not administered (eg, the child moves before the injection is completed)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Administration of expired vaccine</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reconstitution with the wrong diluent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Administration of any of the following vaccines by the subcutaneous rather than the intramuscular (IM) route: hepatitis B vaccine, human papillomavirus vaccine, or <a class="drug drug_pediatric" data-topicid="12940" href="/d/drug information/12940.html" rel="external">inactivated influenza vaccine</a> that is labeled for IM administration</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intradermal administration of any vaccine </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Administration of an <strong>injectable</strong> live virus vaccine (eg, measles, mumps, and rubella vaccine; <a class="drug drug_pediatric" data-topicid="13006" href="/d/drug information/13006.html" rel="external">varicella vaccine</a>) &lt;28 days after another <strong>injectable</strong> live virus vaccine</p><p></p><p>For inactivated vaccines, the invalid dose should be repeated as soon as possible. For live vaccines, the invalid dose should be repeated ≥28 days after the invalid dose.</p><p>Doses of vaccine that are administered ≥5 days before the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fhcp%2Facip-recs%2Fgeneral-recs%2Ftiming.html%23t-02&amp;token=mYAdTABtjfTUPLPFv6f%2FlNbSwAfD2TgcEIHCelQLOkA4aDVnguVXuxeKzQa65jPNHCI3rsWnpLRTRhZ4KP4K7OqgkSsYT7Gw2xg8H5wOb9Q%3D&amp;TOPIC_ID=2876" target="_blank">recommended minimum age or interval</a> are also invalid. Invalid doses of inactivated vaccines should be repeated when the child reaches the minimum age or the recommended minimum interval has elapsed. Invalid doses of live vaccines should be repeated ≥28 days after the invalid dose, provided that the child has reached the recommended minimum age or the recommended minimum interval as elapsed.</p><p>Additional information about how to avoid preventable vaccination errors, and how to respond if they occur, is available from the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.immunize.org%2Fhandouts%2Fadministering-vaccines.asp&amp;token=BVLa7sspEduX8seva3e5RY6qJOjSPrINZ4azMo4Vd3jaPF1UKGx5eWw8zecg44BDVXHddu83TLEKnG6Fwx6cJK8AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=2876" target="_blank">Immunize.org</a>.</p><p class="headingAnchor" id="H2349360624"><span class="h2">Doses that can be counted as valid</span><span class="headingEndMark"> — </span>Nonstandard vaccine administration scenarios that do <strong>not</strong> require repeating the dose include [<a href="#rid55">55</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Vaccine that is recommended to be given subcutaneously is administered IM</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patient sneezes after nasal spray vaccine</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infant regurgitates, spits, or vomits after oral rotavirus vaccine (see  <a class="medical medical_review" href="/d/html/6023.html" rel="external">"Rotavirus vaccines for infants", section on 'Administration'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The dose that was administered was greater than the age-appropriate dose (the parent/caregiver should be notified about the error)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Doses administered &lt;5 days before the minimum recommended age or interval, unless required by local or state mandates</p><p></p><p class="headingAnchor" id="H710153603"><span class="h1">VACCINE STORAGE AND HANDLING</span><span class="headingEndMark"> — </span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fhcp%2Fadmin%2Fstorage%2Findex.html&amp;token=vbqWlkdRAOlBr78RwEqtmg8VvNYcRAUcjxzXeTfYNp4qvp7dOqug4AkW0u6OTP7ua9q5KGkextSITv%2BaxJBL6w%3D%3D&amp;TOPIC_ID=2876" target="_blank">Recommendations for storage and handling of vaccines</a>, including a <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fhcp%2Fadmin%2Fstorage%2Ftoolkit%2Findex.html&amp;token=vbqWlkdRAOlBr78RwEqtmuNBG52MtShfqC32qVVfT5uQDANZuBrtqioQVgNzMNjURlHZ7uGUseX8Qi%2FZohhdTzgmfEop4I79IRT8Q%2FlzNEc%3D&amp;TOPIC_ID=2876" target="_blank">toolkit</a>, are available from the Centers for Disease Control and Prevention.</p><p class="headingAnchor" id="H3838700171"><span class="h1">ADVERSE EVENTS</span></p><p class="headingAnchor" id="H3715912941"><span class="h2">Local and systemic reactions</span><span class="headingEndMark"> — </span>Mild adverse local and systemic reactions occur with approximately 50 percent of vaccinations, depending upon the vaccine [<a href="#rid100">100</a>]. Localized tenderness, erythema, and swelling and/or mild fever are most common [<a href="#rid101">101</a>]. These reactions usually resolve in one to two days without intervention.</p><p>More serious local and systemic reactions may occur. Examples include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Shoulder injury related to vaccine administration/subdeltoid or subacromial bursitis</strong> – The risk of shoulder injury related to vaccine administration is low (approximately 1 per 10,000 intramuscular deltoid muscle injections in a retrospective study of more than 3.7 million vaccinations) [<a href="#rid102">102</a>]. It is lower in children age 3 to 17 years than in adults (0.05 versus 1.22 per 10,000 injections).</p><p></p><p class="bulletIndent1">Clinical features of shoulder injury related to vaccine administration (SIRVA)/ subdeltoid or subacromial bursitis include shoulder pain and reduced range of motion at the shoulder within a few hours of vaccination without evidence of microbial infection [<a href="#rid103">103-109</a>]. Pain and reduced function can be prolonged. Management may include physiotherapy and intra-articular glucocorticoid injections. Proper intramuscular injection technique prevents SIRVA. (See <a class="local">'Immunization technique'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Febrile seizures</strong> – The risk of febrile seizures is slightly increased following certain vaccines or combinations of vaccines. Genetic susceptibility may also play a role. (See  <a class="medical medical_review" href="/d/html/6183.html" rel="external">"Clinical features and evaluation of febrile seizures", section on 'Immunization'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Syncope</strong> – Postvaccination syncope occurs most frequently among adolescents and young adults, and can be associated with serious injury (eg, skull fracture, cerebral hemorrhage) [<a href="#rid110">110</a>]. Among cases of postvaccine syncope reported to the Vaccine Adverse Events Reporting System (VAERS), 80 percent occurred within 15 minutes of vaccination.</p><p></p><p class="bulletIndent1">To prevent secondary injury associated with syncope, the Advisory Committee on Immunization Practices suggests observation of adolescent and young adult patients for 15 minutes after vaccination [<a href="#rid111">111</a>]. This suggestion is particularly important for patients with risk factors for presyncope, even though presyncope does not always progress to syncope. Risk factors for presyncope include a history of passing out or nearly passing out after an injection or venipuncture, prevaccine anxiety, receiving ≥2 shots, and more severe postvaccination pain [<a href="#rid112">112</a>]. Symptoms of presyncope include dizziness, faintness, weakness, lightheadedness, facial flushing, difficulty hearing, visual disturbance, rapid or pounding heartbeat, rapid or difficult breathing, sweating, and feeling cold and sweaty or "clammy." Drinking water 10 to 60 minutes before immunization does not appear to prevent presyncope in adolescents or young adults [<a href="#rid112">112</a>].</p><p></p><p class="headingAnchor" id="H2660022849"><span class="h2">Risk of recurrence</span><span class="headingEndMark"> — </span>Although the risk of recurrence of local and systemic reactions following revaccination is uncertain, observational studies suggest that most patients with mild or moderate adverse events can be safely immunized [<a href="#rid113">113-115</a>]. Published observational studies typically include small numbers of patients, and patients who had severe reactions (eg, anaphylaxis) often are not reimmunized. These limitations notwithstanding, a systematic review of 29 observational studies published between 1982 and 2016 provides estimates of the risk of recurrence of selected adverse effects [<a href="#rid113">113</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Extensive limb swelling following diphtheria, tetanus, acellular pertussis (DTaP) vaccine – In a systematic review of three studies, extensive limb swelling occurred in 56 percent of 98 children after DTaP; all recovered completely</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Seizures – No recurrence in three studies</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pain – Ranged from 9 to 36 percent following diphtheria, tetanus, and pertussis-containing vaccines, depending upon the type of vaccine (whole cell versus acellular) and the dose (eight studies)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Redness and/or swelling ≥5 cm (2 inches) – Ranged from 23 to 67 percent following DTaP, depending upon the dose (three studies)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Redness and/or swelling ≥10 cm (4 inches) – 40 percent (95% CI 12-74) following various vaccines (one study)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypotonic hyporesponsive episodes – Pooled recurrence risk of 0 percent (95% CI 0-0.1) in nine studies</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fever – Ranged from 0 to 84 percent depending upon the vaccine (10 studies)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Persistent crying – 15 to 25 percent for DTaP (two studies)</p><p></p><p class="headingAnchor" id="H4110680295"><span class="h2">Allergic reactions</span><span class="headingEndMark"> — </span>Allergic reactions to vaccines, including the acute management of anaphylaxis and the approach to the patient with suspected vaccine allergy, are discussed separately. (See  <a class="medical medical_review" href="/d/html/392.html" rel="external">"Anaphylaxis: Emergency treatment"</a> and  <a class="medical medical_review" href="/d/html/2074.html" rel="external">"Allergic reactions to vaccines", section on 'Approach to the patient with suspected vaccine allergy'</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Reporting adverse events</span><span class="headingEndMark"> — </span>Adverse events associated with vaccines should be reported to the United States Department of Health and Human Services using <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fvaers.hhs.gov%2Findex.html&amp;token=8m3rK0tzv73hmwLVujPJP%2FVrZTr5LmKIlDf%2BMKp07YKCkZawMmw76Mlq0N%2Fh3R%2BM&amp;TOPIC_ID=2876" target="_blank">VAERS</a> (telephone number 1-800-822-7967).</p><p>The National Childhood Vaccine Injury Act requires health care providers in the United States to report:</p><p class="bulletIndent1"><span class="glyph">●</span>Adverse events listed in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fvaers.hhs.gov%2Fresources%2Finfoproviders.html&amp;token=8m3rK0tzv73hmwLVujPJP0qanY2M2u93cIPAq0RoqzD%2FIHPDqXJfnuzapDi7dT0NXpiIg0MoE3e%2B6xUStdB7RA%3D%3D&amp;TOPIC_ID=2876" target="_blank">VAERS table of reportable events following vaccination</a></p><p class="bulletIndent1"><span class="glyph">●</span>Adverse events that are listed by the vaccine manufacturer</p><p></p><p>The Centers for Disease Control and Prevention also encourages health care providers to report any clinically significant adverse event that occurs after vaccination, even if it is unclear whether the vaccine caused the event [<a href="#rid116">116</a>].</p><p class="headingAnchor" id="H3968372383"><span class="h1">VACCINATION COVERAGE</span><span class="headingEndMark"> — </span>National, regional, and state vaccination coverage (ie, the percentage of eligible children who receive recommended vaccines) estimates for <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fnchs%2Ffastats%2Fimmunize.htm&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLD98c%2FRCgNae%2BIieF6ysbiO1wgNykcqlHaZKe55cZ4rUzxzrEhlWt30h6yoeqwcIpg%3D%3D&amp;TOPIC_ID=2876" target="_blank">children by age 24 month</a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fimz-managers%2Fcoverage%2Fschoolvaxview%2Fdata-reports%2Findex.html&amp;token=GhCi4kcCWrW4eVfWrl2bnuXWOsf4nHcI5qEwJDMstUNE%2BPcf%2Bb5rxhpVBMWqpRms91VYLBL8k0GWv8aUuS6bkTPBnPsaFgtqVPBkWPxNU3z8MMZmh52VHY0ZA4IFDo5U&amp;TOPIC_ID=2876" target="_blank">children enrolled in kindergarten</a>, and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fimz-managers%2Fcoverage%2Fteenvaxview%2Findex.html&amp;token=CVhhc5%2BLNy3VmiRuv1YVmPXyji%2BKa7bpbOkKZbj1m37lpYpvbvZuwryxorYm5u4YNjilMzZAnxE2kFUqcUEkHLD%2BDVk3hEUFM4fqmybDcuc%3D&amp;TOPIC_ID=2876" target="_blank">teenagers</a> are available from the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fimz-managers%2Fcoverage%2Fchildvaxview%2Findex.html&amp;token=A9Ymtmr7XzJM4wLdcspeOrmEJRuLiHApHHlKMUumec%2FStO8GWrUKzGQIZsTHlSLPTrZYs5U%2BKnqjxq2hFNwWsf2QOIMAv0m8oMOPLSkWvkI%3D&amp;TOPIC_ID=2876" target="_blank">Centers for Disease Control and Prevention</a> (CDC). National age-appropriate vaccine coverage generally is &gt;90 percent for most routinely recommended vaccines in preschool- and kindergarten-aged children [<a href="#rid117">117,118</a>]. However, age-appropriate vaccination coverage is lower among preterm infants [<a href="#rid119">119</a>].</p><p>Age-appropriate vaccine coverage is also lower among adolescents, with rates of approximately 90 percent for ≥1 dose of Tdap, 89 percent for ≥1 dose of meningococcal conjugate vaccine, 79 percent for ≥1 dose of human papillomavirus (HPV) vaccine among female adolescents and 75 percent for ≥1 dose of HPV vaccine among male adolescents in 2021 [<a href="#rid120">120</a>]. Fewer adolescents who were due for these vaccines early in the COVID-19 pandemic received them, and they did not catch up [<a href="#rid121">121</a>]. Providers should look for opportunities at all visits to administer tetanus, diphtheria, and acellular pertussis (Tdap), meningococcal conjugate, and human papillomavirus (HPV) vaccines to youth in this cohort who have not received them. Vaccination coverage estimates provided by the CDC do not reflect the timeliness of immunizations [<a href="#rid122">122</a>].</p><p>Provider-focused strategies to increase vaccination coverage include: use of combination vaccines [<a href="#rid9">9,11</a>]; reminder or recall systems, including text messaging [<a href="#rid25">25,123-125</a>]; electronic medical record alerts that the patient is due for specific vaccines; provision of educational brochures in the waiting area [<a href="#rid126">126</a>]; and use of standing orders for immunization to avoid missed opportunities for immunization [<a href="#rid18">18,127</a>]. <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.immunize.org%2Fstanding-orders%2F&amp;token=bJ98wEjwYbR6KcGnbD%2BLoRWJGYdnUf4UzbD41o7inuawQtdwpdoWnq3xo5Mm2x1NfjMOsTbR4L6rLeQW%2FjG5Ew%3D%3D&amp;TOPIC_ID=2876" target="_blank">Immunize.org</a> provides resources for implementing standing orders for immunization. A systematic review of 55 randomized and observational studies concluded that reminder and recall messages probably are effective in increasing immunization rates in primary care (by an average of 8 percent) [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H1319761862"><span class="h1">RESOURCES</span></p><p class="bulletIndent1"><span class="glyph">●</span>The Centers for Disease Control and Prevention provides a number of vaccine-related resources, including:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fhcp%2Fvis%2Fcurrent-vis.html&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLAH%2FK5ePuSCWLS93Qnaa3r%2F5qdQw%2FNYQGK1y%2BHqFU7TkRZLnBxvqrSwSUrCQcXZVSA%3D%3D&amp;TOPIC_ID=2876" target="_blank">Vaccine information statements</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A list of <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fhcp%2Facip-recs%2Fgeneral-recs%2Fcontraindications.html%23t-01&amp;token=6ueO%2FaxldHJpCyCaCNPb7mHVrSmDPVTmUZqlyjUwPWA2E%2BzSFV1qRAZwVZzcsMt7hVW5Sj%2B7i39F1S9Glgtnx1GqqYVj%2BNHr5juvqXVbacY%3D&amp;TOPIC_ID=2876" target="_blank">contraindications and precautions</a> to commonly used vaccines</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww2a.cdc.gov%2Fnip%2Fkidstuff%2Fnewscheduler_le%2F&amp;token=N8qVJSrBCrbuXuD7GKvcN7kvHB54GbGIT4hInvK55XQTTaf%2FrEQp5dUWKcRcEQidurDJqPbDXIIAYmtG89qAeA%3D%3D&amp;TOPIC_ID=2876" target="_blank">Instant Childhood Immunization Schedule</a>, a personal, customized immunization schedule based upon the child's birth date</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Information regarding <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fhcp%2Fadmin%2Fadmin-protocols.html&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLAH%2FK5ePuSCWLS93Qnaa3r%2BukUj05ViRKBL5wyhaXTZ1kK5Dour98IypaLWsUJ21Bw%3D%3D&amp;TOPIC_ID=2876" target="_blank">vaccine administration</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fpubs%2Fpinkbook%2Findex.html&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLPYxS7yIpma2orsm%2BTVpww8w2d%2FmMC8G2EDPT1a9sS%2BQisajaHJZWQcYGNLisQTMZQ%3D%3D&amp;TOPIC_ID=2876" target="_blank">Epidemiology and Prevention of Vaccine-Preventable Diseases</a> (The Pink Book)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An updated list of <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fhcp%2Fclinical-resources%2Fshortages.html&amp;token=E%2FbWRQLLxxHwfbAUtQyg03TroTU9sHx%2FgEUJ%2FcRdpJt8w8Y2eALHBOQ8rIEH%2FYPi6eHQHipTgMLTbxoypLzCbEZ3vPXyls9eLzYKunXSeLQ%3D&amp;TOPIC_ID=2876" target="_blank">vaccine shortages and delays</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>State specific <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fphlp%2Fpublications%2Ftopic%2Fvaccinations.html&amp;token=DLsj7d2M4JeDWUd5lrQ%2BXYamzh9j51lDuN5f9HD5edOtHt65V0Ut2Ip0%2Fi6c0x0lonhmhyBK99ZO8CF3MirDzg%3D%3D&amp;TOPIC_ID=2876" target="_blank">vaccine requirements for daycare and school entry</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fhcp%2Fadmin%2Fresource-library.html&amp;token=StNWg6jKXgoZrRdS7XikOaiQLpYYTi3Pk4CD%2BM9Vc968zq%2BeAxZcF%2BJESbhoGMPeW83CIhdTWzrZQCHVsfemQK8AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=2876" target="_blank">resource library</a> including videos on how to prepare and administer intramuscular, subcutaneous, intranasal, and oral vaccines</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.immunize.org%2F&amp;token=bJ98wEjwYbR6KcGnbD%2BLoejSdbdtDpI4EQKn%2BtqVzWf7RcpJipfWejk%2Bgy%2BCZPR%2F&amp;TOPIC_ID=2876" target="_blank">Immunize.org</a> provides numerous resources for <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.immunize.org%2F&amp;token=bJ98wEjwYbR6KcGnbD%2BLoejSdbdtDpI4EQKn%2BtqVzWf7RcpJipfWejk%2Bgy%2BCZPR%2F&amp;TOPIC_ID=2876" target="_blank">health professionals</a> and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fvaccineinformation.org%2F&amp;token=hAC5nrgJRAh83rPs4U2YNqSAJvAVaLs6rKBPchSxZ8KQVxR84pYNj2H3bntSY1vv&amp;TOPIC_ID=2876" target="_blank">the public</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Institute for Safe Medication Practices provides <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ismp.org%2Fresources%2Frecommendations-practitioners-prevent-vaccine-errors-part-2-analysis-ismp-vaccine-errors%3Fid%3D104&amp;token=Xa%2BMwcqcV5VEr2Bl7sID8WxvjNFIEgeOd%2BNyvcvBMAan5ZoRbOoLDkU8pRJu7rrAqJ5A1OGFQ9UUIe%2FtzOd8%2FQQ3%2F%2BwxsRA8lTPdxvbDKaTJjANoaQgA%2Fm1tRWMzLHZVXOf6JFTK8L5iu9ESOuBJfg%3D%3D&amp;TOPIC_ID=2876" target="_blank">recommendations for practitioners to prevent vaccine errors</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nfid.org%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2FzzFErrsPhjdH4oKZYxgUac%3D&amp;TOPIC_ID=2876" target="_blank">National Foundation for Infectious Diseases</a> and provides resources related to immunizations for adolescents</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The US Food and Drug Administration maintains a list of <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fvaccines-blood-biologics%2Fvaccines%2Fvaccines-licensed-use-united-states&amp;token=wCcUPYLTKXZ5S1UGXUKfKr94oxDQyONzYC1uFsK%2BYnQ2%2B4KaGLMcoHHsAbP1LWfZN0ygLpycExSlzNHyAzL3GOlOTh%2B%2BOgpb44BnyQIFSrI%3D&amp;TOPIC_ID=2876" target="_blank">vaccines licensed in the United States</a></p><p></p><p class="headingAnchor" id="H3534753784"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109228.html" rel="external">"Society guideline links: Immunizations in children and adolescents"</a>.)</p><p class="headingAnchor" id="H63"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword[s] of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15741.html" rel="external">"Patient education: Vaccines for babies and children age 0 to 6 years (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/15742.html" rel="external">"Patient education: Vaccines for children age 7 to 18 years (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/1214.html" rel="external">"Patient education: Why does my child need vaccines? (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/1216.html" rel="external">"Patient education: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/1218.html" rel="external">"Patient education: Vaccines for children age 7 to 18 years (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H2115055251"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Routine schedule</strong> – Universally recommended vaccines for children and adolescents in the United States include: hepatitis B; rotavirus; diphtheria, tetanus, pertussis; <em>Haemophilus influenzae</em> type b; pneumococcal conjugate; inactivated polio; seasonal influenza; COVID-19, measles, mumps, rubella; varicella-zoster virus; hepatitis A; meningococcus; and human papillomavirus  (<a class="graphic graphic_figure graphicRef82617 graphicRef58209" href="/d/graphic/82617.html" rel="external">figure 2A-B</a>). Immunization schedules for other countries are available through the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fimmunizationdata.who.int%2Flisting.html%3Ftopic%3Dvaccine-schedule%26location%3D&amp;token=c1aMGh80n5JfqNiS4zUVhkGZJHzJhW7hYZJMwrVG0LFEFjNX7MxA62uBiY6p7F6hXgl8VfAnRnqUWG6LumPYIJJ9nBP597SAHqgFR7nC42s%3D&amp;TOPIC_ID=2876" target="_blank">World Health Organization</a>. (See <a class="local">'Routine schedule'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Catch-up schedule</strong> – Children who are behind on vaccines should be caught up using the minimum intervals between doses  (<a class="graphic graphic_table graphicRef58271 graphicRef72079" href="/d/graphic/58271.html" rel="external">table 8A-B</a>). It is not necessary to restart the series even when the interval between doses is prolonged. (See <a class="local">'Catch-up schedule'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaccine administration</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The Advisory Committee on Immunization Practices provides best practice recommendations for vaccine administration, including <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fhcp%2Facip-recs%2Fgeneral-recs%2Ftiming.html%23t-02&amp;token=mYAdTABtjfTUPLPFv6f%2FlNbSwAfD2TgcEIHCelQLOkA4aDVnguVXuxeKzQa65jPNHCI3rsWnpLRTRhZ4KP4K7OqgkSsYT7Gw2xg8H5wOb9Q%3D&amp;TOPIC_ID=2876" target="_blank">minimum ages and intervals between vaccine doses</a>, as well as the recommended dose, route, and site of administration for individual vaccines  (<a class="graphic graphic_table graphicRef114641" href="/d/graphic/114641.html" rel="external">table 11</a>). (See <a class="local">'Vaccine administration'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Preadministration counseling includes provision of <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fhcp%2Fvis%2Fcurrent-vis.html&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLAH%2FK5ePuSCWLS93Qnaa3r%2F5qdQw%2FNYQGK1y%2BHqFU7TkRZLnBxvqrSwSUrCQcXZVSA%3D%3D&amp;TOPIC_ID=2876" target="_blank">vaccine information statements</a>, assessing for <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fhcp%2Facip-recs%2Fgeneral-recs%2Fcontraindications.html&amp;token=sNGgq5VkfSaPHLmX%2FyNS2NujPwEAot7zqSbWqNH0vSPGn6dBXKG78J8uYDX6HXTCxeMN8cKDGumsphZDQg5hrjwLwn5jOqpCiNWWeYI75AA%3D&amp;TOPIC_ID=2876" target="_blank">contraindications and precautions</a>, and educating parents/caregivers and patients about management of vaccine-related pain. (See <a class="local">'Preadministration counseling'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Most of the routinely recommended childhood vaccines are injected intramuscularly or subcutaneously  (<a class="graphic graphic_table graphicRef114641" href="/d/graphic/114641.html" rel="external">table 11</a>). The preferred position of the child, site of injection, and strategies to reduce injection pain vary with age  (<a class="graphic graphic_table graphicRef114644" href="/d/graphic/114644.html" rel="external">table 12</a>). (See <a class="local">'Injectable vaccines'</a> above and <a class="local">'Reducing injection pain'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reporting adverse events</strong> – Adverse events associated with vaccines should be reported to the United States Department of Health and Human Services using the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fvaers.hhs.gov%2Findex.html&amp;token=8m3rK0tzv73hmwLVujPJP%2FVrZTr5LmKIlDf%2BMKp07YKCkZawMmw76Mlq0N%2Fh3R%2BM&amp;TOPIC_ID=2876" target="_blank">Vaccine Adverse Events Reporting System</a> (telephone number 1-800-822-7967). (See <a class="local">'Reporting adverse events'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Maciosek MV, LaFrance AB, Dehmer SP, et al. Updated Priorities Among Effective Clinical Preventive Services. Ann Fam Med 2017; 15:14.</a></li><li><a class="nounderline abstract_t">Whitney CG, Zhou F, Singleton J, et al. Benefits from immunization during the vaccines for children program era - United States, 1994-2013. MMWR Morb Mortal Wkly Rep 2014; 63:352.</a></li><li><a class="nounderline abstract_t">Talbird SE, Carrico J, La EM, et al. Impact of Routine Childhood Immunization in Reducing Vaccine-Preventable Diseases in the United States. Pediatrics 2022; 150.</a></li><li class="breakAll">Immunize.org; CDC statistics demonstrate dramatic declines in vaccine-preventable diseases when compared with the pre-vaccine era. Available at: https://www.immunize.org/wp-content/uploads/catg.d/p4037.pdf (Accessed on July 29, 2022).</li><li><a class="nounderline abstract_t">Meissner HC. Why is herd immunity so important. AAP News 2015; 36:14.</a></li><li><a class="nounderline abstract_t">Rashid H, Khandaker G, Booy R. Vaccination and herd immunity:  what more do we know? Curr Opin Infect Dis 2012; 25:243.</a></li><li><a class="nounderline abstract_t">Wodi AP, Murthy N, McNally VV, et al. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2024. MMWR Morb Mortal Wkly Rep 2024; 73:6.</a></li><li><a class="nounderline abstract_t">Zangwill KM, Eriksen E, Lee M, et al. A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization. Pediatrics 2008; 122:e1179.</a></li><li><a class="nounderline abstract_t">Marshall GS, Happe LE, Lunacsek OE, et al. Use of combination vaccines is associated with improved coverage rates. Pediatr Infect Dis J 2007; 26:496.</a></li><li><a class="nounderline abstract_t">Guerra FA, Blatter MM, Greenberg DP, et al. Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a preschool booster dose: a randomized, clinical trial. Pediatrics 2009; 123:301.</a></li><li><a class="nounderline abstract_t">Kurosky SK, Davis KL, Galindo CM. Effect of Combination Vaccines on Hepatitis B Vaccine Compliance in Children in the United States. Pediatr Infect Dis J 2017; 36:e189.</a></li><li><a class="nounderline abstract_t">Wodi AP, Murthy N, McNally V, et al. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2023. MMWR Morb Mortal Wkly Rep 2023; 72:137.</a></li><li><a class="nounderline abstract_t">Nelson NP, Weng MK, Hofmeister MG, et al. Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020. MMWR Recomm Rep 2020; 69:1.</a></li><li><a class="nounderline abstract_t">Society for Adolescent Health and Medicine. Establishing an Immunization Platform for 16-Year-Olds in the United States. J Adolesc Health 2017; 60:475.</a></li><li><a class="nounderline abstract_t">Bernstein HH, Bocchini JA Jr, COMMITTEE ON INFECTIOUS DISEASES. Practical Approaches to Optimize Adolescent Immunization. Pediatrics 2017; 139.</a></li><li><a class="nounderline abstract_t">Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep 2020; 69:1.</a></li><li><a class="nounderline abstract_t">Meites E, Kempe A, Markowitz LE. Use of a 2-Dose Schedule for Human Papillomavirus Vaccination - Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2016; 65:1405.</a></li><li><a class="nounderline abstract_t">Pickering LK, Baker CJ, Freed GL, et al. Immunization programs for infants, children, adolescents, and adults: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:817.</a></li><li class="breakAll">Kroger A, Bahta L, Hunter P. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP) Timing and spacing of immunobiologics. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html (Accessed on September 28, 2022).</li><li class="breakAll">Centers for Disease Control and Prevention. Medical Examination of Immigrants and Refugees. www.cdc.gov/immigrantrefugeehealth/exams/medical-examination.html (Accessed on March 22, 2018).</li><li class="breakAll">American Academy of Pediatrics. Children who received immunizations outside the United States or whose immunization status is unknown or uncertain. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.96.</li><li class="breakAll">Kroger A, Bahta L, Hunter P. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP) Special situations. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/special-situations.html (Accessed on January 20, 2022).</li><li><a class="nounderline abstract_t">Paz-Bailey G, Adams L, Wong JM, et al. Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021. MMWR Recomm Rep 2021; 70:1.</a></li><li class="breakAll">Dengue virus infections 2015 case definition. Laboratory criteria for diagnosis. https://ndc.services.cdc.gov/case-definitions/dengue-virus-infections-2015/ (Accessed on February 21, 2022).</li><li><a class="nounderline abstract_t">Jacobson Vann JC, Jacobson RM, Coyne-Beasley T, et al. Patient reminder and recall interventions to improve immunization rates. Cochrane Database Syst Rev 2018; 1:CD003941.</a></li><li><a class="nounderline abstract_t">Nguyen GC, Seow CH, Maxwell C, et al. The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. Gastroenterology 2016; 150:734.</a></li><li><a class="nounderline abstract_t">Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11:286.</a></li><li><a class="nounderline abstract_t">Julsgaard M, Christensen LA, Gibson PR, et al. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection. Gastroenterology 2016; 151:110.</a></li><li class="breakAll">Kroger A, Bahta L, Hunter P. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). Altered immunocompetence. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html (Accessed on January 20, 2022).</li><li><a class="nounderline abstract_t">Evans DI, Shaw A. Safety of intramuscular injection of hepatitis B vaccine in haemophiliacs. BMJ 1990; 300:1694.</a></li><li class="breakAll">Kroger A, Bahta L, Hunter P. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). Vaccine administration. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html (Accessed on January 20, 2022).</li><li><a class="nounderline abstract_t">Taddio A, McMurtry CM, Shah V, et al. Reducing pain during vaccine injections: clinical practice guideline. CMAJ 2015; 187:975.</a></li><li><a class="nounderline abstract_t">Taddio A, Shah V, Leung E, et al. Knowledge translation of the HELPinKIDS clinical practice guideline for managing childhood vaccination pain: usability and knowledge uptake of educational materials directed to new parents. BMC Pediatr 2013; 13:23.</a></li><li><a class="nounderline abstract_t">Taddio A, Ipp M, Vyas C, et al. Teaching parents to manage pain during infant immunizations: laying the foundation for better pain management practices. Clin J Pain 2014; 30:987.</a></li><li><a class="nounderline abstract_t">Taddio A, Shah V, Bucci L, et al. Effectiveness of a hospital-based postnatal parent education intervention about pain management during infant vaccination: a randomized controlled trial. CMAJ 2018; 190:E1245.</a></li><li><a class="nounderline abstract_t">Taddio A, Shah V, McMurtry CM, et al. Procedural and Physical Interventions for Vaccine Injections: Systematic Review of Randomized Controlled Trials and Quasi-Randomized Controlled Trials. Clin J Pain 2015; 31:S20.</a></li><li><a class="nounderline abstract_t">Shaw FE Jr, Guess HA, Roets JM, et al. Effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination. Vaccine 1989; 7:425.</a></li><li><a class="nounderline abstract_t">de Lalla F, Rinaldi E, Santoro D, Pravettoni G. Immune response to hepatitis B vaccine given at different injection sites and by different routes: a controlled randomized study. Eur J Epidemiol 1988; 4:256.</a></li><li><a class="nounderline abstract_t">Beirne PV, Hennessy S, Cadogan SL, et al. Needle size for vaccination procedures in children and adolescents. Cochrane Database Syst Rev 2018; 8:CD010720.</a></li><li><a class="nounderline abstract_t">Diggle L, Deeks JJ, Pollard AJ. Effect of needle size on immunogenicity and reactogenicity of vaccines in infants: randomised controlled trial. BMJ 2006; 333:571.</a></li><li><a class="nounderline abstract_t">Poland GA, Borrud A, Jacobson RM, et al. Determination of deltoid fat pad thickness. Implications for needle length in adult immunization. JAMA 1997; 277:1709.</a></li><li><a class="nounderline abstract_t">Groswasser J, Kahn A, Bouche B, et al. Needle length and injection technique for efficient intramuscular vaccine delivery in infants and children evaluated through an ultrasonographic determination of subcutaneous and muscle layer thickness. Pediatrics 1997; 100:400.</a></li><li><a class="nounderline abstract_t">Jackson LA, Starkovich P, Dunstan M, et al. Prospective assessment of the effect of needle length and injection site on the risk of local reactions to the fifth diphtheria-tetanus-acellular pertussis vaccination. Pediatrics 2008; 121:e646.</a></li><li><a class="nounderline abstract_t">Beirne PV, Hennessy S, Cadogan SL, et al. Needle size for vaccination procedures in children and adolescents. Cochrane Database Syst Rev 2015; :CD010720.</a></li><li class="breakAll">American Academy of Pediatrics. Vaccine administration. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.26.</li><li><a class="nounderline abstract_t">Lippert WC, Wall EJ. Optimal intramuscular needle-penetration depth. Pediatrics 2008; 122:e556.</a></li><li><a class="nounderline abstract_t">WHO. Reducing pain at the time of vaccination: WHO position paper, September 2015-Recommendations. Vaccine 2016; 34:3629.</a></li><li><a class="nounderline abstract_t">Taddio A, Ilersich AL, Ipp M, et al. Physical interventions and injection techniques for reducing injection pain during routine childhood immunizations: systematic review of randomized controlled trials and quasi-randomized controlled trials. Clin Ther 2009; 31 Suppl 2:S48.</a></li><li><a class="nounderline abstract_t">Ipp M, Taddio A, Sam J, et al. Vaccine-related pain: randomised controlled trial of two injection techniques. Arch Dis Child 2007; 92:1105.</a></li><li class="breakAll">Administration of vaccines. In The Australian Immunisation Handbook, 10th ed. Available at: http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook10-home (Accessed on August 16, 2017).</li><li><a class="nounderline abstract_t">Cook IF. An evidence based protocol for the prevention of upper arm injury related to vaccine administration (UAIRVA). Hum Vaccin 2011; 7:845.</a></li><li><a class="nounderline abstract_t">Wadman M. Vaccines on trial. Science 2017; 356:370.</a></li><li><a class="nounderline abstract_t">Behrens RH, Patel V. Avoiding shoulder injury from intramuscular vaccines. Lancet 2021; 397:471.</a></li><li class="breakAll">Immunize.org. Ask the experts. Administering vaccines. Available at: https://www.immunize.org/askexperts/administering-vaccines.asp (Accessed on January 20, 2022).</li><li><a class="nounderline abstract_t">Guerra FA, Gress J, Werzberger A, et al. Safety, tolerability and immunogenicity of VAQTA given concomitantly versus nonconcomitantly with other pediatric vaccines in healthy 12-month-old children. Pediatr Infect Dis J 2006; 25:912.</a></li><li><a class="nounderline abstract_t">Nolan T, Bernstein H, Blatter MM, et al. Immunogenicity and safety of an inactivated hepatitis A vaccine administered concomitantly with diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines to children less than 2 years of age. Pediatrics 2006; 118:e602.</a></li><li><a class="nounderline abstract_t">Dagan R, Amir J, Livni G, et al. Concomitant administration of a virosome-adjuvanted hepatitis a vaccine with routine childhood vaccines at age twelve to fifteen months: a randomized controlled trial. Pediatr Infect Dis J 2007; 26:787.</a></li><li><a class="nounderline abstract_t">Trofa AF, Klein NP, Paul IM, et al. Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with Diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines in children 15 months of age. Pediatr Infect Dis J 2011; 30:e164.</a></li><li><a class="nounderline abstract_t">Rinderknecht S, Michaels MG, Blatter M, et al. Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with measles-mumps-rubella and varicella vaccines in children less than 2 years of age. Pediatr Infect Dis J 2011; 30:e179.</a></li><li><a class="nounderline abstract_t">Staples JE, Gershman M, Fischer M, Centers for Disease Control and Prevention (CDC). Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59:1.</a></li><li><a class="nounderline abstract_t">Ipp M, Parkin PC, Lear N, et al. Order of vaccine injection and infant pain response. Arch Pediatr Adolesc Med 2009; 163:469.</a></li><li><a class="nounderline abstract_t">Taddio A, Appleton M, Bortolussi R, et al. Reducing the pain of childhood vaccination: an evidence-based clinical practice guideline. CMAJ 2010; 182:E843.</a></li><li><a class="nounderline abstract_t">Taddio A, Flanders D, Weinberg E, et al. A randomized trial of rotavirus vaccine versus sucrose solution for vaccine injection pain. Vaccine 2015; 33:2939.</a></li><li><a class="nounderline abstract_t">Horn MI, McCarthy AM. Children's responses to sequential versus simultaneous immunization injections. J Pediatr Health Care 1999; 13:18.</a></li><li class="breakAll">Report to SAGE on reducing pain and distress at the time of vaccination. March 2015. Available at: http://www.who.int/immunization/sage/meetings/2015/april/1_SAGE_latest_pain_guidelines_March_24_Final.pdf?ua=1 (Accessed on August 15, 2017).</li><li><a class="nounderline abstract_t">Meeting of the Strategic Advisory Group of Experts on immunization, April 2015: conclusions and recommendations. Wkly Epidemiol Rec 2015; 90:261.</a></li><li class="breakAll">Report of the SAGE Working Group on vaccine hesitancy. October 2014. Available at: http://www.who.int/immunization/sage/meetings/2014/october/1_Report_WORKING_GROUP_vaccine_hesitancy_final.pdf (Accessed on August 15, 2017).</li><li><a class="nounderline abstract_t">Taddio A, Chambers CT, Halperin SA, et al. Inadequate pain management during routine childhood immunizations: the nerve of it. Clin Ther 2009; 31 Suppl 2:S152.</a></li><li><a class="nounderline abstract_t">Taddio A, Ipp M, Thivakaran S, et al. Survey of the prevalence of immunization non-compliance due to needle fears in children and adults. Vaccine 2012; 30:4807.</a></li><li><a class="nounderline abstract_t">Shah V, Taddio A, McMurtry CM, et al. Pharmacological and Combined Interventions to Reduce Vaccine Injection Pain in Children and Adults: Systematic Review and Meta-Analysis. Clin J Pain 2015; 31:S38.</a></li><li><a class="nounderline abstract_t">Birnie KA, Chambers CT, Taddio A, et al. Psychological Interventions for Vaccine Injections in Children and Adolescents: Systematic Review of Randomized and Quasi-Randomized Controlled Trials. Clin J Pain 2015; 31:S72.</a></li><li><a class="nounderline abstract_t">Pillai Riddell R, Taddio A, McMurtry CM, et al. Psychological Interventions for Vaccine Injections in Young Children 0 to 3 Years: Systematic Review of Randomized Controlled Trials and Quasi-Randomized Controlled Trials. Clin J Pain 2015; 31:S64.</a></li><li><a class="nounderline abstract_t">Birnie KA, Noel M, Chambers CT, et al. Psychological interventions for needle-related procedural pain and distress in children and adolescents. Cochrane Database Syst Rev 2018; 10:CD005179.</a></li><li><a class="nounderline abstract_t">Trottier ED, Doré-Bergeron MJ, Chauvin-Kimoff L, et al. Managing pain and distress in children undergoing brief diagnostic and therapeutic procedures. Paediatr Child Health 2019; 24:509.</a></li><li><a class="nounderline abstract_t">Harrison D, Larocque C, Bueno M, et al. Sweet Solutions to Reduce Procedural Pain in Neonates: A Meta-analysis. Pediatrics 2017; 139.</a></li><li><a class="nounderline abstract_t">Taddio A, Riddell RP, Ipp M, et al. Relative effectiveness of additive pain interventions during vaccination in infants. CMAJ 2017; 189:E227.</a></li><li><a class="nounderline abstract_t">Gupta NK, Upadhyay A, Agarwal A, et al. Randomized controlled trial of topical EMLA and breastfeeding for reducing pain during wDPT vaccination. Eur J Pediatr 2013; 172:1527.</a></li><li><a class="nounderline abstract_t">Harrison D, Reszel J, Bueno M, et al. Breastfeeding for procedural pain in infants beyond the neonatal period. Cochrane Database Syst Rev 2016; 10:CD011248.</a></li><li><a class="nounderline abstract_t">Bos-Veneman NGP, Otter M, Reijneveld SA. Using feeding to reduce pain during vaccination of formula-fed infants: a randomised controlled trial. Arch Dis Child 2018; 103:1132.</a></li><li><a class="nounderline abstract_t">Harrison D, Stevens B, Bueno M, et al. Efficacy of sweet solutions for analgesia in infants between 1 and 12 months of age: a systematic review. Arch Dis Child 2010; 95:406.</a></li><li><a class="nounderline abstract_t">Stevens B, Yamada J, Ohlsson A, et al. Sucrose for analgesia in newborn infants undergoing painful procedures. Cochrane Database Syst Rev 2016; 7:CD001069.</a></li><li><a class="nounderline abstract_t">Kassab M, Foster JP, Foureur M, Fowler C. Sweet-tasting solutions for needle-related procedural pain in infants one month to one year of age. Cochrane Database Syst Rev 2012; 12:CD008411.</a></li><li><a class="nounderline abstract_t">Thyr M, Sundholm A, Teeland L, Rahm VA. Oral glucose as an analgesic to reduce infant distress following immunization at the age of 3, 5 and 12 months. Acta Paediatr 2007; 96:233.</a></li><li><a class="nounderline abstract_t">Shah PS, Aliwalas L, Shah V. Breastfeeding or breastmilk to alleviate procedural pain in neonates: a systematic review. Breastfeed Med 2007; 2:74.</a></li><li><a class="nounderline abstract_t">Pillai Riddell RR, Bucsea O, Shiff I, et al. Non-pharmacological management of infant and young child procedural pain. Cochrane Database Syst Rev 2023; 6:CD006275.</a></li><li><a class="nounderline abstract_t">Harrington JW, Logan S, Harwell C, et al. Effective analgesia using physical interventions for infant immunizations. Pediatrics 2012; 129:815.</a></li><li><a class="nounderline abstract_t">Yilmaz G, Caylan N, Oguz M, Karacan CD. Oral sucrose administration to reduce pain response during immunization in 16-19-month infants: a randomized, placebo-controlled trial. Eur J Pediatr 2014; 173:1527.</a></li><li><a class="nounderline abstract_t">Gates M, Hartling L, Shulhan-Kilroy J, et al. Digital Technology Distraction for Acute Pain in Children: A Meta-analysis. Pediatrics 2020; 145.</a></li><li><a class="nounderline abstract_t">Chambers CT, Taddio A, Uman LS, et al. Psychological interventions for reducing pain and distress during routine childhood immunizations: a systematic review. Clin Ther 2009; 31 Suppl 2:S77.</a></li><li><a class="nounderline abstract_t">Berberich FR, Landman Z. Reducing immunization discomfort in 4- to 6-year-old children: a randomized clinical trial. Pediatrics 2009; 124:e203.</a></li><li><a class="nounderline abstract_t">Chan E, Hovenden M, Ramage E, et al. Virtual Reality for Pediatric Needle Procedural Pain: Two Randomized Clinical Trials. J Pediatr 2019; 209:160.</a></li><li><a class="nounderline abstract_t">Eijlers R, Utens EMWJ, Staals LM, et al. Systematic Review and Meta-analysis of Virtual Reality in Pediatrics: Effects on Pain and Anxiety. Anesth Analg 2019; 129:1344.</a></li><li><a class="nounderline abstract_t">Das RR, Panigrahi I, Naik SS. The effect of prophylactic antipyretic administration on post-vaccination adverse reactions and antibody response in children: a systematic review. PLoS One 2014; 9:e106629.</a></li><li><a class="nounderline abstract_t">Prymula R, Siegrist CA, Chlibek R, et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. Lancet 2009; 374:1339.</a></li><li><a class="nounderline abstract_t">Doedée AM, Boland GJ, Pennings JL, et al. Effects of prophylactic and therapeutic paracetamol treatment during vaccination on hepatitis B antibody levels in adults: two open-label, randomized controlled trials. PLoS One 2014; 9:e98175.</a></li><li><a class="nounderline abstract_t">Wysocki J, Center KJ, Brzostek J, et al. A randomized study of fever prophylaxis and the immunogenicity of routine pediatric vaccinations. Vaccine 2017; 35:1926.</a></li><li><a class="nounderline abstract_t">Braccio S, Saliba V, Ramsay M, Ladhani SN. Question 1: Does prophylactic paracetamol prevent fever after vaccination in infants? Arch Dis Child 2015; 100:1178.</a></li><li class="breakAll">Meningococcal B (MenB) vaccination programme. Available at: https://www.gov.uk/government/collections/meningococcal-b-menb-vaccination-programme (Accessed on July 31, 2017).</li><li class="breakAll">Study assessing the effect of medications to prevent fever on Prevenar 13. Available at: https://clinicaltrials.gov/ct2/show/NCT01392378 (Accessed on July 31, 2017).</li><li class="breakAll">Centers for Disease Control and Prevention. Possible side-effects from vaccines. Available at: https://www.cdc.gov/vaccines/vac-gen/side-effects.htm (Accessed on August 21, 2017).</li><li><a class="nounderline abstract_t">Babl FE, Lewena S, Brown L. Vaccination-related adverse events. Pediatr Emerg Care 2006; 22:514.</a></li><li><a class="nounderline abstract_t">Zheng C, Duffy J, Liu IA, et al. Risk for Shoulder Conditions After Vaccination: A Population-Based Study Using Real-World Data. Ann Intern Med 2022; 175:634.</a></li><li><a class="nounderline abstract_t">Cross GB, Moghaddas J, Buttery J, et al. Don't aim too high: Avoiding shoulder injury related to vaccine administration. Aust Fam Physician 2016; 45:303.</a></li><li><a class="nounderline abstract_t">Salmon JH, Geoffroy M, Eschard JP, Ohl X. Bone erosion and subacromial bursitis caused by diphtheria-tetanus-poliomyelitis vaccine. Vaccine 2015; 33:6152.</a></li><li><a class="nounderline abstract_t">Cook IF. Subdeltoid/subacromial bursitis associated with influenza vaccination. Hum Vaccin Immunother 2014; 10:605.</a></li><li><a class="nounderline abstract_t">Barnes MG, Ledford C, Hogan K. A "needling" problem: shoulder injury related to vaccine administration. J Am Board Fam Med 2012; 25:919.</a></li><li><a class="nounderline abstract_t">Atanasoff S, Ryan T, Lightfoot R, Johann-Liang R. Shoulder injury related to vaccine administration (SIRVA). Vaccine 2010; 28:8049.</a></li><li><a class="nounderline abstract_t">Hesse EM, Navarro RA, Daley MF, et al. Risk for Subdeltoid Bursitis After Influenza Vaccination: A Population-Based Cohort Study. Ann Intern Med 2020; 173:253.</a></li><li><a class="nounderline abstract_t">Fryhofer SA, Fryhofer GW. Vaccination-Induced Bursitis: Technique Matters. Ann Intern Med 2020; 173:308.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Syncope after vaccination--United States, January 2005-July 2007. MMWR Morb Mortal Wkly Rep 2008; 57:457.</a></li><li class="breakAll">Kroger A, Bahta L, Hunter P. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). Preventing and managing adverse reactions. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/adverse-reactions.html (Accessed on January 20, 2022).</li><li><a class="nounderline abstract_t">Kemper AR, Barnett ED, Walter EB, et al. Drinking Water to Prevent Postvaccination Presyncope in Adolescents: A Randomized Trial. Pediatrics 2017; 140.</a></li><li><a class="nounderline abstract_t">Zafack JG, De Serres G, Kiely M, et al. Risk of Recurrence of Adverse Events Following Immunization: A Systematic Review. Pediatrics 2017; 140.</a></li><li><a class="nounderline abstract_t">Zafack JG, Toth E, Landry M, et al. Rate of Recurrence of Adverse Events Following Immunization: Results of 19 Years of Surveillance In Quebec, Canada. Pediatr Infect Dis J 2019; 38:377.</a></li><li><a class="nounderline abstract_t">Muñoz CE, MacDonald B, Pham-Huy A, et al. Revaccination and Adverse Event Recurrence in Patients with Adverse Events following Immunization. J Pediatr 2022; 250:45.</a></li><li class="breakAll">Vaccine Adverse Event Reporting System. Information for healthcare providers. Available at: https://vaers.hhs.gov/resources/infoproviders.html (Accessed on August 08, 2017).</li><li><a class="nounderline abstract_t">Seither R, Yusuf OB, Dramann D, et al. Coverage with Selected Vaccines and Exemption from School Vaccine Requirements Among Children in Kindergarten - United States, 2022-23 School Year. MMWR Morb Mortal Wkly Rep 2023; 72:1217.</a></li><li><a class="nounderline abstract_t">Hill HA, Yankey D, Elam-Evans LD, et al. Vaccination Coverage by Age 24 Months Among Children Born in 2019 and 2020 - National Immunization Survey-Child, United States, 2020-2022. MMWR Morb Mortal Wkly Rep 2023; 72:1190.</a></li><li><a class="nounderline abstract_t">Hofstetter AM, Jacobson EN, deHart MP, Englund JA. Early Childhood Vaccination Status of Preterm Infants. Pediatrics 2019; 144.</a></li><li><a class="nounderline abstract_t">Pingali C, Yankey D, Elam-Evans LD, et al. National Vaccination Coverage Among Adolescents Aged 13-17 Years - National Immunization Survey-Teen, United States, 2021. MMWR Morb Mortal Wkly Rep 2022; 71:1101.</a></li><li><a class="nounderline abstract_t">Pingali C, Yankey D, Elam-Evans LD, et al. Vaccination Coverage Among Adolescents Aged 13-17 Years - National Immunization Survey-Teen, United States, 2022. MMWR Morb Mortal Wkly Rep 2023; 72:912.</a></li><li><a class="nounderline abstract_t">Hargreaves AL, Nowak G, Frew P, et al. Adherence to Timely Vaccinations in the United States. Pediatrics 2020; 145.</a></li><li><a class="nounderline abstract_t">Stockwell MS, Kharbanda EO, Martinez RA, et al. Text4Health: impact of text message reminder-recalls for pediatric and adolescent immunizations. Am J Public Health 2012; 102:e15.</a></li><li><a class="nounderline abstract_t">Suh CA, Saville A, Daley MF, et al. Effectiveness and net cost of reminder/recall for adolescent immunizations. Pediatrics 2012; 129:e1437.</a></li><li><a class="nounderline abstract_t">Norman DA, Barnes R, Pavlos R, et al. Improving Influenza Vaccination in Children With Comorbidities: A Systematic Review. Pediatrics 2021; 147.</a></li><li><a class="nounderline abstract_t">Scott VP, Opel DJ, Reifler J, et al. Office-Based Educational Handout for Influenza Vaccination: A Randomized Controlled Trial. Pediatrics 2019; 144.</a></li><li class="breakAll">Kroger A, Bahta L, Hunter P. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). Vaccination programs. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/programs.html (Accessed on January 20, 2022).</li></ol></div><div id="topicVersionRevision">Topic 2876 Version 123.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28376457" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Updated Priorities Among Effective Clinical Preventive Services.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24759657" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Benefits from immunization during the vaccines for children program era - United States, 1994-2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35821599" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Impact of Routine Childhood Immunization in Reducing Vaccine-Preventable Diseases in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35821599" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Impact of Routine Childhood Immunization in Reducing Vaccine-Preventable Diseases in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Why is herd immunity so important</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22561998" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Vaccination and herd immunity:  what more do we know?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38206855" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2024.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19047220" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17529866" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Use of combination vaccines is associated with improved coverage rates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19117896" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a preschool booster dose: a randomized, clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28106622" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Effect of Combination Vaccines on Hepatitis B Vaccine Compliance in Children in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36757872" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2023.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32614811" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28340872" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Establishing an Immunization Platform for 16-Year-Olds in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28167515" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Practical Approaches to Optimize Adolescent Immunization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33417592" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27977643" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Use of a 2-Dose Schedule for Human Papillomavirus Vaccination - Updated Recommendations of the Advisory Committee on Immunization Practices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19659433" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Immunization programs for infants, children, adolescents, and adults: clinical practice guidelines by the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19659433" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Immunization programs for infants, children, adolescents, and adults: clinical practice guidelines by the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19659433" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Immunization programs for infants, children, adolescents, and adults: clinical practice guidelines by the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19659433" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Immunization programs for infants, children, adolescents, and adults: clinical practice guidelines by the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19659433" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Immunization programs for infants, children, adolescents, and adults: clinical practice guidelines by the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34978547" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34978547" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29342498" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Patient reminder and recall interventions to improve immunization rates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26688268" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23200982" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27063728" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27063728" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2143948" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Safety of intramuscular injection of hepatitis B vaccine in haemophiliacs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2143948" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Safety of intramuscular injection of hepatitis B vaccine in haemophiliacs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26303247" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Reducing pain during vaccine injections: clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23394070" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Knowledge translation of the HELPinKIDS clinical practice guideline for managing childhood vaccination pain: usability and knowledge uptake of educational materials directed to new parents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24300222" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Teaching parents to manage pain during infant immunizations: laying the foundation for better pain management practices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30348739" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Effectiveness of a hospital-based postnatal parent education intervention about pain management during infant vaccination: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26352919" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Procedural and Physical Interventions for Vaccine Injections: Systematic Review of Randomized Controlled Trials and Quasi-Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2530717" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2969825" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Immune response to hepatitis B vaccine given at different injection sites and by different routes: a controlled randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30091147" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Needle size for vaccination procedures in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16891328" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Effect of needle size on immunogenicity and reactogenicity of vaccines in infants: randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9169899" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Determination of deltoid fat pad thickness. Implications for needle length in adult immunization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9282716" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Needle length and injection technique for efficient intramuscular vaccine delivery in infants and children evaluated through an ultrasonographic determination of subcutaneous and muscle layer thickness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18310184" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Prospective assessment of the effect of needle length and injection site on the risk of local reactions to the fifth diphtheria-tetanus-acellular pertussis vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26086647" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Needle size for vaccination procedures in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26086647" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Needle size for vaccination procedures in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18694903" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Optimal intramuscular needle-penetration depth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26571310" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Reducing pain at the time of vaccination: WHO position paper, September 2015-Recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19781436" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Physical interventions and injection techniques for reducing injection pain during routine childhood immunizations: systematic review of randomized controlled trials and quasi-randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17686797" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Vaccine-related pain: randomised controlled trial of two injection techniques.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17686797" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Vaccine-related pain: randomised controlled trial of two injection techniques.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21832883" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : An evidence based protocol for the prevention of upper arm injury related to vaccine administration (UAIRVA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28450595" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Vaccines on trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33549186" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Avoiding shoulder injury from intramuscular vaccines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33549186" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Avoiding shoulder injury from intramuscular vaccines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17006287" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Safety, tolerability and immunogenicity of VAQTA given concomitantly versus nonconcomitantly with other pediatric vaccines in healthy 12-month-old children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16950952" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Immunogenicity and safety of an inactivated hepatitis A vaccine administered concomitantly with diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines to children less than 2 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17721372" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Concomitant administration of a virosome-adjuvanted hepatitis a vaccine with routine childhood vaccines at age twelve to fifteen months: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21494175" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with Diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines in children 15 months of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21617573" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with measles-mumps-rubella and varicella vaccines in children less than 2 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20671663" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19414694" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Order of vaccine injection and infant pain response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21098062" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Reducing the pain of childhood vaccination: an evidence-based clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25917674" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : A randomized trial of rotavirus vaccine versus sucrose solution for vaccine injection pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10085835" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Children's responses to sequential versus simultaneous immunization injections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10085835" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Children's responses to sequential versus simultaneous immunization injections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26027016" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Meeting of the Strategic Advisory Group of Experts on immunization, April 2015: conclusions and recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26027016" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Meeting of the Strategic Advisory Group of Experts on immunization, April 2015: conclusions and recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19781434" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Inadequate pain management during routine childhood immunizations: the nerve of it.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22617633" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Survey of the prevalence of immunization non-compliance due to needle fears in children and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26201016" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Pharmacological and Combined Interventions to Reduce Vaccine Injection Pain in Children and Adults: Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26348163" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Psychological Interventions for Vaccine Injections in Children and Adolescents: Systematic Review of Randomized and Quasi-Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26201014" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Psychological Interventions for Vaccine Injections in Young Children 0 to 3 Years: Systematic Review of Randomized Controlled Trials and Quasi-Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30284240" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Psychological interventions for needle-related procedural pain and distress in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31844394" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Managing pain and distress in children undergoing brief diagnostic and therapeutic procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27986905" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Sweet Solutions to Reduce Procedural Pain in Neonates: A Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27956393" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Relative effectiveness of additive pain interventions during vaccination in infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23812513" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Randomized controlled trial of topical EMLA and breastfeeding for reducing pain during wDPT vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27792244" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Breastfeeding for procedural pain in infants beyond the neonatal period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29769176" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Using feeding to reduce pain during vaccination of formula-fed infants: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20463370" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Efficacy of sweet solutions for analgesia in infants between 1 and 12 months of age: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27420164" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Sucrose for analgesia in newborn infants undergoing painful procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23235662" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Sweet-tasting solutions for needle-related procedural pain in infants one month to one year of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17429911" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Oral glucose as an analgesic to reduce infant distress following immunization at the age of 3, 5 and 12 months.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17661578" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Breastfeeding or breastmilk to alleviate procedural pain in neonates: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37314064" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Non-pharmacological management of infant and young child procedural pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22508924" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Effective analgesia using physical interventions for infant immunizations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24942239" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Oral sucrose administration to reduce pain response during immunization in 16-19-month infants: a randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31969473" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Digital Technology Distraction for Acute Pain in Children: A Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19781437" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Psychological interventions for reducing pain and distress during routine childhood immunizations: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19596729" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Reducing immunization discomfort in 4- to 6-year-old children: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31047650" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Virtual Reality for Pediatric Needle Procedural Pain: Two Randomized Clinical Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31136330" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Systematic Review and Meta-analysis of Virtual Reality in Pediatrics: Effects on Pain and Anxiety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25180516" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : The effect of prophylactic antipyretic administration on post-vaccination adverse reactions and antibody response in children: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19837254" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24897504" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Effects of prophylactic and therapeutic paracetamol treatment during vaccination on hepatitis B antibody levels in adults: two open-label, randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28262330" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : A randomized study of fever prophylaxis and the immunogenicity of routine pediatric vaccinations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26586519" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Question 1: Does prophylactic paracetamol prevent fever after vaccination in infants?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26586519" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Question 1: Does prophylactic paracetamol prevent fever after vaccination in infants?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26586519" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Question 1: Does prophylactic paracetamol prevent fever after vaccination in infants?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26586519" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Question 1: Does prophylactic paracetamol prevent fever after vaccination in infants?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16871116" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Vaccination-related adverse events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35313110" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Risk for Shoulder Conditions After Vaccination: A Population-Based Study Using Real-World Data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27166466" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Don't aim too high: Avoiding shoulder injury related to vaccine administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26458794" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Bone erosion and subacromial bursitis caused by diphtheria-tetanus-poliomyelitis vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24284281" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Subdeltoid/subacromial bursitis associated with influenza vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23136333" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : A "needling" problem: shoulder injury related to vaccine administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20955829" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Shoulder injury related to vaccine administration (SIRVA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32568572" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Risk for Subdeltoid Bursitis After Influenza Vaccination: A Population-Based Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32568575" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Vaccination-Induced Bursitis: Technique Matters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18451756" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Syncope after vaccination--United States, January 2005-July 2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18451756" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Syncope after vaccination--United States, January 2005-July 2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29061871" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Drinking Water to Prevent Postvaccination Presyncope in Adolescents: A Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28847985" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Risk of Recurrence of Adverse Events Following Immunization: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30882727" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Rate of Recurrence of Adverse Events Following Immunization: Results of 19 Years of Surveillance In Quebec, Canada.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35948192" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Revaccination and Adverse Event Recurrence in Patients with Adverse Events following Immunization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35948192" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Revaccination and Adverse Event Recurrence in Patients with Adverse Events following Immunization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37943705" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Coverage with Selected Vaccines and Exemption from School Vaccine Requirements Among Children in Kindergarten - United States, 2022-23 School Year.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37917561" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Vaccination Coverage by Age 24 Months Among Children Born in 2019 and 2020 - National Immunization Survey-Child, United States, 2020-2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31391213" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Early Childhood Vaccination Status of Preterm Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36048724" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : National Vaccination Coverage Among Adolescents Aged 13-17 Years - National Immunization Survey-Teen, United States, 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37616185" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Vaccination Coverage Among Adolescents Aged 13-17 Years - National Immunization Survey-Teen, United States, 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32086389" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Adherence to Timely Vaccinations in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22390457" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Text4Health: impact of text message reminder-recalls for pediatric and adolescent immunizations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22566415" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Effectiveness and net cost of reminder/recall for adolescent immunizations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33558309" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Improving Influenza Vaccination in Children With Comorbidities: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31292219" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Office-Based Educational Handout for Influenza Vaccination: A Randomized Controlled Trial.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
